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The survival rates for childhood cancer have dramatically increased since the 1960s
and at the start of the 21st century, more than 1 in 1000 young adults in their third
decade was a survivor of childhood cancer. The aim is to achieve a cure with
minimal late effects from the treatment, with the reproductive axis being vulnerable
to both radiotherapy and gonadal toxic chemotherapy. This thesis addresses aspects
of hypothalamic, pituitary, ovarian and uterine function in post pubertal women
following treatment for cancer in childhood.
The effect of low dose cranial irradiation (18-24 Gray) on gonadal function was
evaluated in long-term survivors of childhood leukaemia. Tracking of urine
luteinising hormone (LH), oestrone and pregnandiol demonstrated reduced LH
secretion throughout the cycle and particularly during the LH surge, short luteal
phases and decreased oestrone production. These data indicate that treatment for
childhood leukaemia results in a subtle ovulatory disorder in some patients, probably
related to cranial irradiation.
Women treated for childhood cancer, who have progressed spontaneously through
puberty and have regular menstrual cycles, may still be at risk of an early
menopause. Ovarian reserve was assessed in women with regular menstrual cycles
and women with a history of regular cycles who were using the oral contraceptive
pill (OCP), for contraception. They were investigated before and 24 hours after an
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injection of follicle stimulating hormone (FSH). Women with regular cycles had
significantly higher basal FSH, and lower anti-Mullerian hormone levels, and
reduced ovarian volume. Women on the OCP had a reduced inhibin B response to
FSH and lower antral follicle counts. Therefore, both groups showed hormonal and
biophysical evidence of partial loss of ovarian reserve.
Radiotherapy to the abdomen carries a high risk of ovarian failure. The effect on the
uterus is less well documented. Ovarian and uterine function were evaluated in
women who had received total body irradiation in childhood (14.4 Gray). In women
with ovarian failure, uterine function was evaluated before and after 3 months of
physiological sex steroid replacement (pSSR). At baseline, uterine artery blood flow
and thickening of the endometrium were not detectable. After 3 months of pSSR
neither blood flow or endometrial thickness were different from controls. Uterine
volume remained smaller, and there was a correlation with age at irradiation.
Endometrial samples were obtained and the histology and histochemistry of the
endometrium were normal compared with controls. Hormone replacement therapy
that achieves physiological sex steroid concentrations improves uterine size, blood
flow and endometrial development.
For those young women that have ovarian failure there is no good evidence as to the
optimal method of pubertal induction and subsequent cyclical hormone replacement
therapy. UK practice was evaluated by postal questionnaire sent to all British
Endocrinologists who were members of the European Society for Paediatric
Endocrinology. Therapy for pubertal induction was consistent but there was no
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consensus on the choice of cyclical hormone replacement. Clinicians' choice was
influenced by convenience and acceptability for the patient.
A case is reported of a girl who had clinical and biochemical evidence of ovarian
failure after treatment with pelvic radiotherapy and chemotherapy. Prior to treatment
she had had ovarian cortical tissue stored and consideration was given to re¬
implantation. She had a spontaneous conception, and delivered a healthy baby at
term. The case illustrates the difficulties in evaluation of ovarian failure, choice of
\
HRT and the advice that should be given to young girls regarding fertility.
This work further elucidates the late effects on reproductive health for women treated
for childhood cancer. Uncertainties remain however, regarding the best way to
manage these important health issues, both during treatment and in adult life.
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One in 600 children will develop cancer in the first 15 years of life. Unlike the
majority of adult cancers, most paediatric cancers are curable using multi-agent
chemotherapy in combination with surgery and radiotherapy. The incidence of
childhood cancer is 110 to 130 per million children per year and the relative
frequencies of paediatric cancers are shown in Figure 1.1. Over the last three decades
there has been a sustained improvement in survival for most forms of childhood
cancer. In the 1960s, ALL, the commonest childhood malignancy, had a five-year
survival rate of less than 10%. Today, 70% of these children may now be cured
(Hann et al., 2000). Following the demonstration in the 1950s that actinomycin was
an effective agent in the treatment ofWilms' tumour, there has been steady progress
in the development of multi-agent chemotherapy regimens for the majority of
childhood haematological and solid tumours. Radiotherapy is highly effective in the
treatment of many malignancies but the increasing recognition of the morbidity for
children from the late effects of radiation exposure has limited its therapeutic benefit.
At the start of the 21st century, more than 1 in 1000 young adults in their third decade
was a survivor of childhood cancer and the number of long term survivors continues
to increase. The major challenge for this generation of children's cancer specialists is
to sustain the significant improvement in survival rates while at the same time
minimizing the treatment-induced late effects. The risk of late effects is directly
related to the treatment received. The anticipation of late effects and their detection is
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important as they may be amenable to prevention or treatment (Hawkins and Smith,
1996).
The reproductive system is an important site of late effects of anti-cancer treatment
(Ogilvey-Stuart et al., 1993). Natural pubertal progression, fertility and successful
pregnancy outcome depend on normal hypothalamic, pituitary, ovarian and uterine
function. Potential adverse effects on reproductive function in the female may be
mediated through the hypothalamo-pituitary-ovarian axis (Littley et al., 1989), the
ovary (Wallace et al., 1989) or the uterus (Critchley et al., 1992). One of the more
commonly recognised adverse effects of anti-cancer treatments is ovarian failure as a
result of depletion of the numbers of primordial follicles leading to a premature
menopause (Wallace et al., 2003). However, the late effects of the treatment on
reproductive function are difficult to predict with certainty.
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1.2 Late effects of treatment on ovarian function
1.2.1 Introduction
There is a relationship between age of menopause in childhood cancer survivors and
treatment to which they have been exposed. A review of 1067 women who were
more than 5 years out from treatment for cancer, diagnosed during the teenage years,
demonstrated a risk ofmenopause four times greater than controls during their early
twenties. Significantly increased relative risks ofmenopause occurred after treatment
with either radiotherapy alone (relative risk 3.7) or alkylating agents alone (relative
risk 9.2). Those at greatest risk of an early menopause were women treated with both
radiation below the diaphragm and alkylating agent chemotherapy and by the age of
31, 42% of these women had reached the menopause compared with only 5% of
controls (Byrne et al., 1992).
1.2.2 Radiotherapy
The risk of ovarian damage after radiotherapy is related to radiation dose, schedule
and age at treatment. The primordial follicle is very radiosensitive and the LD50 has
recently been revised at 2 Gy (Wallace et al., 2003). Following a radiation insult, the
size of the surviving population determines the window of opportunity for fertility
and time until the menopause. The depletion of primordial follicles that occurs at the
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time of the insult is related to the number present, so that the younger the woman at
the time of treatment the greater the number of follicles that survive, and the later the
onset of the menopause. In women aged 40 years it has been shown that a permanent
menopause may be induced by 6 Gy (Lushbaugh and Casarett, 1976). For younger
women and children it is likely that a total dose of 20 Gy over 6 weeks would
produce permanent sterility with 95% confidence.
In a study of 38 patients who received whole abdominal radiotherapy (20 -30 Gy) in
childhood, all but one patient developed ovarian failure, (27 experienced pubertal
failure, and a premature menopause occurred in 10 (median age 23.5 years))
(Wallace et al., 1989). The risk of ovarian failure after treatment with total body
irradiation (TBI) as conditioning for a bone marrow transplant is significant but less
predictable. In a large study of 718 long term survivors, treated with chemotherapy
and/or TBI as conditioning treatment before a bone marrow transplant, 532 had
received TBI (10 - 15.75 Gy, single exposure or fractionated) and 186
chemotherapy, with either cyclophosphamide or busulphan (Sanders et al., 1996).
After TBI, 90% developed ovarian failure and after cyclophosphamide or busulphan
60% failed. There were 16 spontaneous pregnancies to 13 women who had received
TBI, 6 of these women were prepubertal at the time of their radiotherapy. In a study
of 16 girls treated prepubertally with TBI, 9 (56%) had spontaneous pubertal
progression, although 6 of these women had increased plasma concentrations of
gonadotrophins (Sarafouglou et al., 1997). The women with ovarian failure were
significantly older at the time of their radiotherapy compared with female patients
with spontaneous puberty (8.6 ±2.3 years vs 6.1 ± 1.8 years).
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1.2.3 Chemotherapy
Chemotherapy causes both early and late effects which limit the dose and schedule
of exposure. The impact of combination cytotoxic chemotherapy on gonadal function
is dependent on the nature and total dosage of the drugs received by the child. The
ovary is chemosensitive, and agents that are recognized to cause gonadal damage are
listed in Table 1.1. There is a trend towards intensification of treatment, particularly
with childhood leukaemia. Thus the risk of gonadal damage with these evolving
regimens needs to be continually evaluated.
The majority of early reports of ovarian function in children treated with
combination chemotherapy for acute lymphoblastic leukaemia suggest that
premature ovarian failure is uncommon (Siris et al., 1976; Pasqualini et al., 1987;
Green et al., 1989). In a UK study of 40 girls treated in childhood for ALL, all
achieved adult pubertal development and 37 had regular menses. There were 14 live
births in nine long-term survivors with no serious congenital abnormalities and no
reported cases ofmalignant disease (Wallace et al., 1993). However there have been
reports of premature ovarian failure in women treated for ALL with more intensive
regimens. Quigley et al (1989) found significantly high basal and peak FSH levels
following GnRH administration in prepubertal and pubertal girls. All the girls
reached puberty at a normal time and had normal oestradiol levels. Modern treatment
for childhood ALL in the UK seems unlikely to be sterilizing although these women
may be at increased risk of a premature menopause.
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Early reports of ovarian function following the treatment of Hodgkin's disease in
childhood (Bramswig et al., 1989) suggested that ovarian function was normal in all
women studied. However, a study of 32 women treated with ChlVPP (chlorambucil,
vinblastine, procarbazine and prednisilone) and no radiotherapy below the diaphragm
demonstrated raised gonadotrophin levels with variable oestradiol levels in 53%
(Mackie et al., 1996). Seven women had achieved eleven normal pregnancies, and
two of these women had raised gonadotrophins before conception. Follow up of
these women is required to determine whether there is recovery of ovarian function
or progression to a premature menopause.
Ovarian function in children treated with cyclophosphamide (up to 200mg/kg) as
conditioning for BMT was reported as normal in 95%, higher doses in excess of
200m/kg may result in premature ovarian failure (Sanders et al., 1991). Current
studies are evaluating the effect of ifosfamide on ovarian function. As all these drugs
are rarely used as single chemotherapy agents, accurate assessment of the gonadal
toxicity remains complex. New chemotherapy agents and multiagent chemotherapy
protocols need to be continually evaluated to determine the risk of late effects.
1.2.4 Cranial irradiation
Hypothalamic - pituitary function shows progressive compromise following high
dose cranial irradiation (> 30Gy). The risk relates both to the dose and whether the
primary pathology involves the pituitary gland. Littley and colleagues demonstrated
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that the risk of gonadotrophin deficiency was 60% 4 years out from treatment, but
these subjects had pituitary adenomas as the primary pathology (Littley et al., 1989).
For those patients who have received high dose cranial irradiation for tumours not
involving the pituitary the risk of gonadotrophin deficiency is significantly lower,
and has been reported as 2-6 % for 40 - 50 Gy, 20 - 50% for greater than 50 Gy
(Gleeson and Shalet, 2004). Low dose CNS directed radiotherapy, as part of
treatment for ALL, has been associated with subtle perturbations in growth hormone
secretion (Crowne et al., 1992; Brennan et al., 1998) but there are few reports
assessing effect on other pituitary hormone secretion in adulthood (Birkebaek et al.,
1998). In a study of reproduction following treatment for childhood ALL in the
Scandinavian countries, women who had received prophylactic radiation of the CNS
had a significantly lower first birth rate than those without radiation, indicating that
doses of 18 - 24 Gy to the brain may be a possible risk factor (Nygaard et al., 1991).
For those women with confirmed hypogonadotrophic hypogondism after cranial
radiotherapy, ovulation induction may be achieved with pulsed gonadotrophin
therapy.
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1.3 Late effects of treatment on uterine function
1.3.1 Radiotherapy
Several studies have demonstrated that uterine function is compromised by radiation
exposure. Following whole abdominal irradiation (20 - 30 Gy) in childhood, all
pregnancies occurring in women with preserved ovarian function resulted in mid
trimester miscarriage (Wallace et al., 1989). The women with ovarian failure
secondary to whole abdominal irradiation (20 -30 Gy) had a significantly reduced
uterine length, which showed no improvement in size, blood flow or endometrial
thickness when exposed to physiological sex steroid replacement for one month
(Critchley et al., 1990). Women treated with TBI (10 - 15.75 Gy) with preserved
ovarian function also have an increased risk ofmiscarriage, premature delivery and
low birth weight (Sanders et al., 1996). Six of 16 pregnancies for 13 TBI recipients
were tenninated by spontaneous miscarriage. Six of the girls who were pregnant had
received their treatment prepubertally. Of the six pregnancies, five resulted in
spontaneous miscarriage and one an elective termination of pregnancy. There were
therefore no live offspring to girls treated prepubertally. There were 8 live births, 5
of which were premature, 4 of these babies were of low birth weight and one very
low birth weight.
Uterine volume post TBI has been assessed during standard hormone replacement
and has been shown to be significantly reduced compared to controls (Holm et al.,
1999). A successful pregnancy outcome for women whose uterus has been exposed
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to radiotherapy prepubertally may be compromised. Women treated post pubertally
were noted to have a larger uterine volume and viable pregnancies have been
reported for this group. The effects of radiation are thought to be both on the uterine
musculature, with fibrosis and loss of distensibility, and on uterine artery blood flow.
For women with premature ovarian failure the potential for pregnancy has been made
a realistic possibility with ovum donation and IVF technologies. Pregnancy has been
achieved for women who have ovarian failure secondary to radiation exposure. The
only live offspring reported are to women whose uterus has been exposed to
radiotherapy post pubertally. Oocyte donation achieved conceptions in 2 of 3 women
who were treated with TBI for a haematological malignancy; one woman with a
uterus of almost normal size, who was treated postpubertally, delivered a healthy girl
at term and one woman with a small uterine volume, who was treated pre/peri
pubertally, conceived but had a spontaneous mid trimester miscarriage (Larsen et al,
2000).
1.3.2 Chemotherapy
There is no evidence that chemotherapy has a significant long term effect on uterine
function. There are no reports in the literature of an increased risk ofmiscarriage and
there are many reports of normal pregnancy outcome following multi agent
chemotherapy protocols (Quigley et al., 1989; Nicholson and Byrne, 1993).
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1.4 Conclusion
The identification of late effects of the treatment of childhood cancer enables future
physicians to pursue the ethos of achieving a cure while minimizing the risk of long
term effects from the treatment. With the intensification of treatment strategies
children will remain at risk of infertility, secondary to the therapies employed.
Evaluation of late effects and novel strategies for preserving reproductive potential
enables informed best practice for preserving the reproductive potential for children
who require treatment for cancer.
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CHAPTER 2: Ovarian and uterine function - normal
physiology and investigation of function
41
2.1 Introduction
In the post pubertal female, tightly coordinated functions between the hypothalamus
and pituitary gland, the ovary and the endometrium give rise to cyclical predictable
menses that indicate regular ovulation. An understanding of the normal physiology is





The evolution of this process starts with germ cell migration. The premeiotic germ
cells arrive at the genital ridge by the 5th week. The number of germ cells increases
and peaks at 20 weeks gestation with 6 to 7 x 106 follicles. There is then an
inexorable decline, secondary to follicle atresia, with 1 to 2 x 106 follicles present at
birth, 300,000 by the onset of puberty, and less than 1000 when the menopause
occurs. There is therefore, a relationship between age and number of follicles in
human ovaries (Block., 1952), with an accelerated decline in follicle number from
age 35 (Faddy et al., 1992). Of these follicles only 400 - 500 will ovulate during the
reproductive lifespan.
The ovary is made of the outer cortex and inner stroma. The outer cortex consists of
the germinal epithelium and the follicles. Each ovarian follicle comprises an egg, the
oocyte, surrounded by granulosa cells, which in turn are surrounded by theca cells.
The follicle is the functional unit of the ovary. The majority of the follicles are in a
non growing stale, termed the primordial follicle. The recruitment ofprimordial
follicles to primary follicles is controlled by local ovarian factors, and continues
independently of hypothalamic pituitary control. The follicle matures from
primordial to a primary and then a secondary follicle - the preantral stage. Under
gonadotrophin control, the follicle further matures to an antral follicle. This is
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therefore only possible once the hypothalamic pituitary gonadal axis has matured
through puberty. Post puberty, the ovary has two main objectives, to produce
fertilisable ovum and prepare the endometrium for implantation.
Plasma levels ofLH and FSH rise in the fetus after establishment of the
hypothalamic pituitary portal system, until mid gestation, and then fall towards term
as inhibitory influences, the sex steroids, rise towards term. During the first 2 years
of life, plasma levels ofLH and FSH rise intermittently, and from mid childhood the
plasma levels remain low until puberty. Puberty involves changes in the central
nervous system and an increase in the frequency and amplitude ofLHRH secretion,
which initiates and regulates the secretion of pituitary gonadotrophins and gonadal
sex steroids that promote development of secondary sexual characteristics. There is
an increase in the amplitude ofLH and FSH secretion at night from about 5 years of
age. The amplitude and frequency of these peaks increase and daytime secretion
increases with the progression of pubertal development.
The major oestrogen in females is oestradiol, which is principally secreted by the
ovary. In the fetus and at term, oestradiol levels are high because of conversion of
the fetal and adrenal C19 steroids to oestradiol by the placenta. The plasma levels
drop precipitously in the first few days of life. Levels remain very low until the onset
of puberty. Studies with ultra sensitive assays have shown gradually increasing levels
of oestradiol prior to the clinical onset of puberty, consistent with the gradual
increase in FSH. In puberty oestradiol in secreted by the granulosa cells, under
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control ofFSH. LH stimulates androstenedione production from the theca cells
which is peripherally converted to oestradiol.
Progesterone is the principal secretory product of the corpus luteum, and is
responsible for the progestational effects of cell differentiation and the induction of
secretory activity in the endometrium. Progesterone is therefore required for
implantation of the fertilised ovum and maintenance of pregnancy.
Inhibin is a peptide produced by the granulosa cells, and has a major regulatory role
in FSH production by the pituitary. Inhibin is a heterodimer, composed of common a
subunit and different p subunits, denoted Pa and Pb, termed A and B respectively.
Both isoforms have similar properties, but synthesis is regulated differently
throughout the cycle. Inhibin B is secreted during the early follicular phase,
decreasing in the mid follicular phase, and is undetectable after the LH surge. Inhibin
A is low during the first half of the follicular phase, and increases during the mid
follicular phase with a peak during the luteal phase. Levels are low during childhood,
and the positive relationship with FSH indicates that sporadic follicular development
through infancy and childhood is under the influence of FSH. Both increase during
puberty and the relationship to FSH changes from mid puberty, to that seen in post
puberty (Crofton et al., 2002)
Onset ofmenses occurs with complex interaction of sex steroids, ovarian peptides
and gonadotrophins. Increasing FSH allows for follicle growth and development, and
increasing oestradiol secretion. The mid cycle surge ofLH stimulates rupture of
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follicle and release of egg, and formation of the corpus luteum. Progesterone and
oestradiol are secreted by the corpus luteum. Oestradiol induces growth of the
endometrium and progesterone enhances differentiation. Sloughing of the
endometrium follows withdrawal of oestradiol and progesterone as the corpus luteum
involutes in the absence of pregnancy.
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2.3 Investigation of hypothalamic and ovarian function
2.3.1 Biochemical assessment
In infancy the hypothalamic - ovarian axis is active and gonadotropin levels are
detectable. However, these levels fall, and remain low until the onset of puberty. The
activity of the hypothalamus, and the production of LH and FSH can be investigated
with stimulation tests, that are principally employed to detect precocious or
premature puberty in young girls (Zevenhuijzen et al., 2004). Biochemical detection
of gonadal damage is not reliable in prepuberty, although stimulation tests may
reveal a brisk FSH response, in late prepuberty, in those with ovarian failure.
Elevated baseline gonadotrophin levels, as the early manifestation of ovarian failure,
may be detectable in infancy, as may be seen in young girls with Turners syndrome,
or when a child is of an age and physical maturity appropriate for the onset of
puberty. Failure of development of secondary sexual characteristics at an age
appropriate time, with rising gonadotrophins are suggestive of ovarian failure.
Elevated gonadotrophins, undetectable oestradiol and failure of pubertal progression
indicate ovarian failure and the need for oestrogen replacement for pubertal
induction, progressing to cyclical hormone replacement post pubertally.
Detection of subtle hypothalamic/pituitary ovarian dysfunction and prediction of a
premature menopause are difficult. Early follicular phase assay of FSH, oestradiol
and inhibin B are potential tools to assess ovarian reserve. While there are few direct
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data on changes in these markers in the context of chemotherapy or radiotherapy,
there is considerable evidence for their value in detecting the changes associated with
normal ageing, and as predictors of the ovarian response to superovulation which is
believed to be an index of the total follicular pool (Cruz et al., 1996). A rise in early
follicular phase FSH with maintained oestrogen production is well recognised to be a
feature of the perimenopause (Sherman et al., 1976; Reyes et al., 1977), and is
detectable from approximately 20 years before the menopause (Ahmed Ebbiary et
al., 1994). The pattern of secretion of inhibin B across the menstrual cycle is
consistent with secretion by the developing cohort of follicles, while inhibin A is
predominantly secreted by the dominant follicle (Groome et al., 1994; Groome et al.,
1996; Welt et al., 1997). Inhibin B concentrations are reduced in the early follicular
phase in older women (Klein et al., 1999; Welt et al., 1999) and are correlated with
the ovarian response to exogenous gonadotrophin stimulation (Seifer et al., 1997;
Hall et al., 1999; Eldar-Geva et al., 2000). Inhibin B appears to be the earliest
endocrine marker of the perimenopause (Burger et al., 1998).
2.3.2 Radiological assessment
Imaging of the ovary and uterus through childhood and puberty has shown changes
consistent with biochemical assessments, and parallels the clinical findings of
puberty as described by Marshall and Tanner (Marshall et al., 1976). Pelvic
ultrasound has proved to be an accurate, painless and non-invasive investigation in
the assessment of internal genitalia. Uterine and ovarian growth are correlated both
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with age, in the prebubertal child, and pubertal stage (Herter et al., 2002). A cross-
sectional study of 166 girls aged 6-18 years, investigated ovarian and uterine shape
and morphology in relation to pubertal stage (Holm et al., 1995). The appearance of
breast development was preceded by growth and development of the internal female
genitalia. The median (range) ovarian volume in the prepubertal girls was 1.2 mis
(0.5 - 5.1 mis). Ovarian growth was most pronounced between breast stages 2 and 4.
Median ovarian volumes were 2.2mls, 4.1 mis, 6.2 mis, and 7.3 mis for puberty
stages 2,3,4 and 5 respectively. Follicle activity was seen in 87% of prepubertal girls.
From the age of 14-15 years, the size of follicles began to increase and vary
considerably, reflecting that girls were in different stages of the menstrual cycle.
Ovarian volume has been shown to decline with age in the post pubertal women
(Wallace et al., 2004). Other workers have demonstrated that antral follicle count
showed the best correlation with women's age, and declined linearly at a rate of
3.8% per year (Ng et al., 2003). Ovarian volume has been shown to predict the
number of recruitable follicles during super ovulation (Syrop et al., 1999).
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2.4 Investigation of uterine function.
2.4.1 Radiological assessment
Ultrasound scanning is a reliable non-invasive technique for assessing uterine size
and shape, blood supply and endometrial thickness. The uterine shape changes
through puberty and is a useful indicator of pubertal stage. Normal uterine length and
volume for pre, peri and post puberty are well documented (Holm et al., 1995). In
this study, uterine volume increased before clinical evidence of onset of puberty. The
volume continued to increase through puberty with the greatest increase in size
occurring between Tanner stages 3 and 4. The gains achieved after menarche were
also significant, with uterine volume increasing up to age 20 years. No correlation
was found between uterine volume and the height of the girls. The uterine volumes
were 1.6 (0.7 - 7.9) mis, 2.8 (1.3 - 8.1) mis, 8.0 (2.0 - 18) mis, 37 (11 - 56) mis, 43
(12 - 82) mis and 61 (37 - 130) mis for Tanner breast stages 1, 2, 3, 4, 5 and adult
respectively. A study of young girls with Turner syndrome documented normal
uterine growth in those with preserved ovarian function, but in those who required
pubertal induction with exogenous steroids, 50% did not achieve normal adult
uterine dimensions (Paterson et al, 2002).
Uterine artery blood flow may be assessed by Doppler scanning and quantified as the
pulsatility index indicating degree of resistance to flow, distal to the point of
sampling (Taylor et al, 1985; Steer et al, 1990). Diastolic flow has been
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demonstrated in 35% of prebubertal females and 100% of normal adult women with
regular menses (Laursen et al, 1996).
2.4.2 Histological assessment
Endometrial biopsy may be performed as an out patient using a Pipelle endometrial
sampler that obtains a piece of the endometrium by aspiration (Sauer et al., 1997;
Critchley at al., 2004). It can be performed without cervical dilatation and is
therefore usually associated with minimal discomfort. Endometrial function may
then be assessed by histology (Noyes et al., 1950) and with immunno-histological
techniques (Snidjers et al., 1992; Critchley et al., 1998).
CHAPTER 3: Aims of thesis
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3.1 Aims
The purpose of this thesis is to investigate the long term effect of cytotoxic treatment
(radiotherapy and/or chemotherapy) on the reproductive health ofwomen treated for
childhood cancer. Long term survivors were studied to help elucidate these issues.
The hypotheses were that
1. there are subtle effects on hypothalamic and ovarian function following non
sterilising therapy for childhood cancer.
2. ovarian reserve can be predicted using biochemical and radiological
investigation
3. the uterus is significantly affected by radiotherapy but parameters can be
improved by optimising hormone replacement therapy
4. there is no consensus on hormone replacement therapy for young women
with ovarian failure
The majority ofwomen are treated with non-sterilising therapy that may have a
significant effect on hypothalamic or ovarian function that is only clinically apparent
when they present with infertility, irregular menses or premature ovarian failure.
Investigation of the risk of hypothalamic or ovarian effects and tests to aid in
determining reserve would therefore be extremely valuable in elucidating the risk for
these women. The effect of low dose cranial irradiation (18-24 Gray) on gonadal
function was evaluated in long-term survivors of childhood leukaemia. Ovarian
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reserve was assessed in women who had been treated with chemotherapy in
childhood. We assessed women with regular menstrual cycles and women with a
history of regular cycles who were using the COCP for contraception. A significant
number ofwomen use the COCP and there is no literature regarding ovarian
assessment while on the COCP. They were investigated before and 24 hours after an
injection ofFSH to assess baseline ovarian function and in response to stimulation.
For those women with ovarian failure secondary to radiotherapy to the pelvis, the
effect on the uterus is not well characterised. Optimising oestrogen and progesterone
replacement may improve uterine function. Ovarian and uterine function were
evaluated in women who had received total body irradiation in childhood (14.4
Gray). In women with ovarian failure, uterine function was evaluated before and
after 3 months of pSSR.
For those young women who have ovarian failure there is no good evidence as to the
optimal method of pubertal induction and subsequent cyclical hormone replacement
therapy to maximise skeletal, cardiovascular, reproductive and psychological well
being. UK practice was evaluated to determine whether there was a consensus.
A case is reported of a girl who had clinical and biochemical evidence of ovarian
failure after treatment with pelvic radiotherapy and chemotherapy. The case
elucidates the difficulties in biochemical assessment of ovarian failure, optimising
hormone replacement therapy and accurate advice regarding fertility potential.
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CHAPTER 4: Hypothalamic - Pituitary - Ovarian
dysfunction after prepubertal chemotherapy and cranial
irradiation for acute leukaemia
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4.1 Introduction
The majority of children presenting now with ALL will be cured (Chessels et al.,
1995). In the 1960s the cure rate was less than 5%. Increased survival over the
following twenty years was achieved with chemotherapy and radiotherapy and by the
1980s the survival rate had risen to 70%. This allowed a shift in aim over the last 20
years to reducing treatment related effects while further improving the survival rate.
While high dose cranial radiation is recognised to significantly compromise
hypothalamic - pituitary function, the effects of the relatively low dose irradiation
for childhood leukaemia are uncertain. Reports of ovarian function after treatment of
standard risk childhood leukaemia have been reassuring (Wallace et al., 1993),
however the relatively recent advances in treatment, and thus survival mean that few
patients are beyond their 30th birthday. We have therefore carried out a detailed
investigation of hypothalamo-pituitary-ovarian function in long-term survivors of
childhood ALL.
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4.2 Materials and methods
Women were eligible for recruitment to this study if they were in first clinical
remission following treatment for ALL (chemotherapy with cranial irradiation) in
childhood or early adolescence, five or more years out from end of treatment and
were post-pubertal at the time of recruitment. Thirty such women were identified
from the long-term follow up clinic at The Royal Hospital for Sick Children,
Edinburgh. Eighteen were excluded from assessment: one woman was pregnant, 8
were using hormonal contraception, 7 declined to take part and 2 had ongoing
medical problems. Twelve women were therefore recruited for participation in the
study. Sixteen healthy women with regular menstrual cycles were recruited as
normal controls. They were recruited by two methods: a) a poster campaign
requested women who had regular menses, were not on the OCP and aged 18-30
years and were interested in taking part in a research study to contact the study
coordinator and b) by a special study module student (a research module during 4th
year of undergraduate training) who approached friends who were also
undergraduates, regarding participation in a research study.
The combination chemotherapy schedules were the Medical Research Council
studies UKALL I, II, V, VIII and X. All these protocols included the use of
vincristine, 6 mercaptopurine, prednisolone and methotrexate. Other drugs used in
some schedules included asparaginase, cytosine arabinoside, doxorubicin and
cyclophosphamide. The protocols evolved with increasing intensity of chemotherapy
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with subsequent protocols. All patients received cranial irradiation in a total dose of
18 - 24 Gy, depending on the protocol, and 2 patients received in addition spinal
irradiation (dose 10-14 Gy), which has been documented to have a direct effect on
ovarian function in some patients.
4.2.1 Subjects details
The 12 women recruited following treatment for ALL had median age at diagnosis of
4.7 years (1.9 - 13.1), and at assessment 20.8 years (15.8 - 32.8) (see table 4.1).
Mean BMI was 25.8±1.2kg/m2. The controls were aged 17.3 - 29.0 years (median
24.1), with regular menstrual cycles (25-32 days) and had not used hormonal
contraception in the preceding 3 months. Mean BMI was 23.3±1.2kg/m . A full
menstrual and pregnancy history was taken from subjects and controls, and all were
confirmed to be euthyroid and have normal prolactin concentrations.
The local ethics committee gave approval for the study and informed consent was
obtained from all women.
4.2.2 Study design
The women collected a daily early morning urine sample from day 1 of the cycle for
a minimum of 2 cycles in ALL patients (total of 41 cycles) and 1 cycle in controls.
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Table 4.1 Patient details








1 ALL 3.2 UKALL VII 1800 N 16.3
2 ALL 3.9 UKALLI 2500 1000 30.1
3 ALL 1.9 CHOP 1800 N 22
4 ALL 5.5 UKALLX 1800 N 17.3
5 ALL 2.1 UKALL II 2400 N 19.5
6 ALL 11.2 UKALL II 2400 1000 32.6
7 ALL 3.2 UKALL VII 1800 N 16.8
8 ALL 6 UKALLV 1800 N 23.2
9 ALL 10 UKALLX 1800 N 17.3
10 ALL 7.2 UKALLV 1800 N 23.7
11 ALL 2.2 UKALLV 1800 N 16
12 ALL 13.1 UKALL VII 1800 N 24.3
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Preliminary data suggested that cycle characteristics were more variable in ALL
patients than controls, thus repeated cycles were collected and analysed where
possible. At least 3 cycles were collected by 9 of the ALL patients. While control
women initially collected 2 consecutive cycles, in view of the consistency of cycle
characteristics in these women, only 1 cycle per woman was included in the detailed
analysis to give the normal comparison group.
All women also attended during the early follicular phase (day 3-5) of a cycle for
blood sampling and ultrasound scan of the ovaries. Blood samples were analysed for
plasma E2, P4, LH, FSH, inhibin A and B, IGF1 and IGFBP3 and prolactin. All
ultrasound examinations were performed by one of two radiologists trained in
gynaecological scanning using a Hitachi EUB 555. Scans were performed
transvaginal^ (6.5 MHz transducer) in sexually active women and transabdominal^
(3.5 MHz transducer) in those who were not. Ovarian volume was measured in three
orthogonal diameters and using the formula for a prolate ellipsoid (dixd2xd3) x 0.523
(Holm et al., 1996).
4.2.3 Hormone analyses
Urine samples were analysed for luteinising hormone (LH), oestrone conjugates
(E1C) and pregnanediol-3-glucuronide (P3G). Urinary E1C and P3G were measured
using an "in house" ELISA using HRP-conjugate as label and solid-phase second
antibody separation (for E1C, CV < 4%; for P3G, CV <13%). Urinary LH was
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measured by a two-site IRMA (Serono MAIA clone, CV < 12%). Urinary hormone
concentrations were corrected for creatinine concentration. Serum E2 was measured
by competitive immunoassay using the Boehringer Mannheim Elecsys (Mannheim,
Germany). P4, FSH and LH were measured by microparticle enzyme immunoassay
on the Abbott Axsym (Chicago, Illinois). Inhibin A and B were measured by two-site
ELISAs as previously reported (Groome et al., 1994). For inhibin B assay sensitivity
was 7.8 pg/ml, intra- and inter-plate CVs were 10.6% and 11.4% respectively and for
inhibin A intra- and inter-plate CVs were 5.0% and 12.7% respectively. IGF1 and
IGFBP3 were measured as previously described (Blum., 1996).
4.2.4 Statistical analysis
The day of onset ofmenses was defined as cycle day 1, and the last day of the cycle
was that preceding the next menstruation, giving cycle length. The last day of the
follicular phase was the day of the onset of the LH surge, defined as a minimum of a
2.5-fold rise in LH excretion over the mean LH concentration in the preceding 4
days. Follicular and luteal steroid excretion was calculated as the integrated area
under the curve using the trapezoid method over the relevant part of the cycle (total
follicular phase, days 2-5 and days 6-12 to give measures of early and late follicular
phases, and total luteal phase). Peak luteal P3G was calculated as the mean of the 3
consecutive days of maximal excretion, and the LH surge was quantified as the sum
of values of the 3 days from the onset of the LH surge. Follicular LH excretion was
calculated as the mean of the first 7 days of the cycle.
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Hormonal data are presented as mean ± sem. Data were log transformed to correct
non-equality of variance and compared by ANOVA and Student's t test. Initial
comparisons investigated differences between controls and all ALL women's cycles.
If this indicated a significant difference, data were further analysed by ANOVA after
subdivision of ALL patient cycles into those with normal or short luteal phases,
cycles with a luteal phase length of <11 days being defined as short. Data showing
significant non-equality of variance (cycle characteristics and ovarian volume) were




All 12 women treated for childhood ALL had achieved adult sexual development and
the onset ofmenses. They reported regular menstrual cycles (26 - 30 days), and this
was confirmed during the study when ovulatory cycles were demonstrated in all
subjects. None had been pregnant. A total of 41 cycles from ALL patients were
analysed (table 4.2). 2 cycles from ALL patients were anovulatory (no LH surge and
no rise in P3G), both in women who also had normal ovulatory cycles. These 2
cycles were excluded from further analysis. No anovulatory cycles were seen in the
control women.
Overall cycle length was not different in ALL patients (table 4.2) compared to
controls (table 4.3) (28.1±0.5 vs. 28.7±0.7 days, figure 4.1). Length of the follicular
phase was also similar (15.9±0.4 vs. 15.2±0.6 days) but the length of the luteal phase
was significantly shorter in ALL patients (12.2±0.3 vs. 13.6±0.4 days, p=0.01).
Closer analysis of luteal phase length indicated a high prevalence of short (<11 days)
luteal phases in ALL patients, whereas only 1 such cycle was seen in controls.
Overall, 15 out of 39 apparently ovulatory cycles in ALL patients showed short
luteal phases, in 5 of the 12 patients. Short luteal phases were not always
consistently seen in those ALL patients who demonstrated them: all 4 cycles from
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Table 4.2 Details of number of completed cycles each patient
collected urine samples and each cycle length and length of luteal
phase in days
Pt no No of
cycles
Cycle length Luteal length
1 2 29,27 (1 anov) 13,12
2 4 28,35,31,25 15,14,14,14
3 3 27,28,26 12,11,12
4 1 30(1 anov) 14
5 5 27,25,26,25,27 10,10,10,12,11
6 4 22,26,25,25 8,9,10,10
7 2 36,35 11,13
8 5 28,28,29,30,26 10,12,16,13,10
9 3 27,34,30 13,15,15
10 5 26,24,24,30,26 13,11,12,13,11
11 3 34,31,29 14,14,13
12 2 128,26 12,11
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Table 4.3 Details of the cycles of the control women during which
urine samples were collected


















Figure 4.1 Cycle length in controls (open bars) and ALL subjects
(filled bars). Total cycle length, and duration of the follicular and




one subject showed short luteal phases, but cycles with normal luteal length were
also seen in the other 4 patients. These cycles are hereafter referred to as 'short' and
'normal' ALL cycles in distinction to control cycles (i.e. in normal, control women).
ALL patients with short luteal phases did not differ in age at initial treatment or age
at present investigation from those who only showed normal luteal phase length
(figure 4.2). There was however a significantly greater interval between initial
treatment and time of present investigation in those showing short luteal phases
(p=0.04), consistent with a progressive effect of treatment. BM1 did not differ
between the two groups (26.1±0.6 kg/m2, normal cycle group; 25.4±1.9 kg/m2, short
luteal cycle group).
4.3.2 Urinary hormone excretion
Detailed analysis of daily urinary hormone excretion revealed several differences
between ALL patients and controls. During the follicular phase, LH excretion was
lower in ALL patients than controls (p=0.002, figure 4.3a), with lowest levels in
short luteal phase cycles which were significantly different both from controls
(p=0.005) and ALL cycles with normal luteal phase length (p=0.03). Normal length
ALL cycles had lower LH levels than control cycles (p=0.05). A more marked
difference in LH excretion was seen during the LH surge (figure 4.3b). Mean 3 day
LH excretion was significantly lower in ALL cycles than controls (p<0.0001), with
both short and normal ALL cycles showing this difference (p=0.0005 and p=0.004
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Figure 4.2 Age at initial treatment, present investigation, and
interval since treatment in ALL patients who showed cycles with
short luteal phases (n=5, open bars) and those who only showed











Age at Age at Interval since
treatment investigation treatment
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Figure 4.3 Urinary LH excretion in control and ALL subject cycles.
(a) Mean day 1-7 LH excretion in controls (open bars, n=16) and
ALL subjects (filled bars, n=39). The stippled and hatched bars
represent LH excretion in the ALL subgroups of cycles with short
(n=15) and normal (n=24) luteal phase length respectively. *





Control ALL Short Normal
ALL subgroup
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(b) Urinary LH excretion in control and ALL subject cycles. Daily
LH excretion centred on the day of onset of the LH surge (cycle
day 0) in control cycles (filled circles, n=16) and cycles or ALL
subjects with normal (open triangles, n=24) and short (n=15)
luteal lengths. Mean ± sem.
Day relative to LH surge
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respectively vs control). There was no significant difference between normal and
short ALL cycles in this respect. LH excretion remained lower in ALL patients than
controls throughout the luteal phase (figure 4.3b).
Follicular phase E1C excretion during both early (days 2-5) and late (days 6-12)
follicular phase was lower in ALL cycles (p=0.01 in both cases, figure 4.4a and
4.4b). Reduced excretion was only lower than control in normal ALL cycles
(p=0.007 and p=0.001, early and late follicular phases) whereas there were no
differences between control and short ALL cycles. E1C excretion was lower in
normal than short ALL cycles at both stages of the follicular stage (p=0.02 in both
cases).
Luteal phase excretion of E1C was also lower in ALL cycles that controls (p=0.01)
(figure 4.4c). Reduced excretion of E1C was detected in both normal and short ALL
cycles compared to controls (p=0.04 and p=0.03 respectively), but there was no
significant difference between normal and short ALL cycles. Luteal phase P3G was
slightly but not significantly lower in ALL cycles than controls, both when analysed
as a 3 day peak or total luteal phase excretion (figure 4.4d).
4.3.3 Plasma hormones
Blood samples taken during the early follicular phase of the cycle were analysed for
LEI, FSH, E2, inhibin A and inhibin B concentrations (tables 4.4 and 4.5). LH and
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Figure 4.4 Urinary steroid excretion in control and ALL subject
cycles, (a) Early and (b) late follicular phase E1G; (c) luteal phase
E1G; (d) luteal phase P3G. Controls (open bars, n=16), ALL
subjects (filled bars, n=39). The stippled and hatched bars
represent LH excretion in the subgroups of ALL patient cycles
with short (n=15) and normal (n=24) luteal phase length
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Table 4.4 Biochemical results of patients on day 3-5 of cycle




1 6.8 5.2 118 77.5
2 6 2.6 152 128.6
3 6.2 3.2 82 51.8
4 5.8 3.5 169 114.5
5 5.6 4.1 169 138.3
6 4.9 2.9 90 65..8
7 5 4.7 125 130.6
8 4.2 2 91 28.7
9 4 3.4 116 84
10 10.3 4.4 71 82.2
11 5.4 2.6 99 90.9
12 5.9 7 82 110.2
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Table 4.5. Biochemical results of controls on day 3-5 of cycle.




1 3.7 2.3 110 32
2 4.7 6.5 86 156
3 5.2 6.2 305 165
4 4.9 4.6 188 214
5 8.3 4.2 275 277
6 6.1 3.9 267 106
7 6 3.7 113 104
8 5.9 4.1 128 175
9 7.8 2.7 147 72
10 7 2.9 136 49
11 7.2 3.1 132 130
12 5.9 3.8 98 108
13 7.8 3.9 156 91
14 3.4 4.6 97 87
15 5.7 5.4 156 59
16 5.8 3.9 117 99
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Figure 4.5 Early follicular phase serum hormones in control and
ALL subjects. Controls, open bars, n=16; ALL subjects, filled
bars, n=12. * p<0.05 vs control. Mean ± sem.
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FSH concentrations were similar in ALL patients to controls (figure 4.5a), but E2
was lower in ALL patients than controls (p=0.032, figure 4.5b). Inhibin A and B
were similar in ALL patients and controls (figure 4.5c and 4.5d). IGF1 and IGFBPs
were compared to published reference ranges (Blum., 1996) and were not
significantly different from the reference range.
4.3.4 Ovarian volumes
Mean ovarian volume in the ALL group was 4.8±0.54 ml, which was not
significantly different from that in controls (5.4±0.57 ml). Ovarian morphology was
normal in all subjects.
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4.4 Discussion
The treatment of childhood cancers frequently involves administration of drugs and
radiation with potential adverse effects on reproductive function. There are few
published data regarding long term follow up of fertility after standard treatment for
ALL (Wallace et al., 1993; Nygaard et al., 1991). While fertility and successful
pregnancies have been reported in patients after the treatment of childhood ALL with
standard MRC regimens (and indeed 3 of the 30 patients identified but not studied
here had had successful pregnancies), this does not rule out a significant and
progressive effect on reproductive function. In a study of reproduction following
treatment for childhood ALL in the Scandinavian countries, women who had
received prophylactic radiation of the CNS had a significantly lower first birth rate
than those without radiation, indicating that doses of 18 - 24 Gy to the brain may be
a possible risk factor (Nygaard et al., 1991). Detailed analysis of endocrine function
at long term follow up has not been previously reported.
We hypothesised that chemotherapy might have reduced the number of
primordial/primary follicles in the ovary of patients with ALL. This was assessed by
early follicular phase hormone assay and by ultrasound measurement of ovarian
volume. ALL patients did not show higher FSH concentrations or lower inhibin A
and B concentrations than controls, or have smaller ovaries. These results therefore
appear to be reassuring as to the number of primordial follicles remaining in the
ovaries of these young girls after chemotherapy for ALL. The lack of sensitivity of
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the available markers and very limited longitudinal data (Welt et al., 1999) suggests,
however, that such reassurance should be limited to stating that there was no
evidence of any subjects being in the peri-menopause. Further longitudinal data are
required to assess the predictive value of these apparently normal results in this
context.
By contrast, daily analysis of urinary hormone excretion provided clear evidence of
abnormal reproductive function in some ALL patients. The great majority of
monitored cycles in ALL patients were ovulatory, based on the presence of an LH
surge and a rise in P3G excretion. This was consistent with the regular menses
reported by these patients. However LH excretion was reduced in ALL patients
throughout the cycle, most markedly during the LH surge. There was also a high
prevalence of cycles with short luteal phases in the ALL patients. While we have no
direct evidence that this is related to reduced LH secretion in these patients, the LH
surge was most deficient in cycles with short luteal phases. It is well recognised that
the function of the corpus luteum is dependent on LH secretion (Hutchison et al.,
1984) and in particular the magnitude and duration of the LH surge (Zelinski-
Wooten et al., 1991). The apparent variability in the prevalence of short luteal
phases between and within subjects (although based on small numbers) is consistent
with the observed partial reduction in the magnitude of the LH surge rather than a
more complete inability to mount the surge. Furthermore, the interval between
treatment and investigation was longer in those patients showing short luteal defects,
consistent with a progressive effect. Pituitary function shows progressive
compromise following cranial irradiation in higher dose than received by the patients
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described here (Littley et al., 1989). Low dose central nervous system directed
radiotherapy, as part of treatment for ALL, has been previously associated with
perturbations in growth hormone secretion (Crowne et al., 1992; Brennan et al.,
1998) but there are no previous reports of an effect on other pituitary hormone
secretion in adulthood (Birkebaek et al., 1998).
Growth hormone (GH) is the primary stimulator of the synthesis of insulin-like
growth factor 1. GH insufficiency has been associated with decreased fertility
(Pellicer et al., 1994). IGF1 may amplify the effects of gonadotrophins on ovarian
tissue (Barreca et al., 1993) and has been postulated to have an effect on uterine
receptivity (Potashnik et al., 1995). In this study, levels of IGF 1 were within the
normal range and did not show a correlation with time since treatment. These data do
not suggest a significant GH deficiency in these patients. However, subtle defects in
GH secretion may not be detected by IGF1 analysis.
Excretion of E1G was significantly lower in the follicular phase in ALL cycles.
Early follicular serum oestradiol concentrations were also lower in ALL patients. As
oestradiol production requires both LH and FSH (The European Recombinant LH
study group., 1998), this may reflect a reduction in gonadotrophs stimulus that was
detected in the reduced urinary LH excretion in ALL patients. There was also
evidence for reduced steroid excretion during the luteal phase, particularly in cycles
with short luteal phases. This reached statistical significance only for ElG excretion,
reflecting the greater intercycle variability in P3G excretion.
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Luteal insufficiency has been reported in the women with infertility and in female
athletes. The role of luteal phase deficiency in causing infertility has been disputed
because the diagnosis is not predictive of recurrence in subsequent cycles and studies
have not revealed better outcome with progesterone treatment (Dawood, 1994).
However, abnormalities in luteal phase have been detected in virtually all stimulation
protocols used in vitro fertilization, partly due to decreased luteal LH secretion and
insufficient corpus luteal function. Progesterone supplementation improves
endometrial histology, and its necessity has been well established (Tavaniotou et al.,
2001).
There is evidence for luteal insufficiency in female athletes. Exercising women with
amenorrhoea exhibit a hypometabolic state. In female athletes with regular menses, a
high proportion of cycles have been shown to be characterized by luteal phase
deficiency with short luteal phase, reduced luteal progesterone excretion and reduced
early follicular oestradiol excretion (De Souza et al., 1998, 2003). Disruption in LH
pulsatility is seen as a primary factor in the high frequency of luteal phase defects in
exercising women. These alterations may represent a metabolic adaption to an
intermittent short-term negative energy balance.
Current fertility prospects for this group of survivors appear good, as evidenced by
successful pregnancies in 3 of the 30 long-term survivors identified. However, this
cohort is still young, with the majority not having tested their fertility. While none of
the women showed evidence of overt ovarian damage, this may reflect our inability
to detect this until relatively late when a woman has entered the perimenopause. The
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risk of premature menopause following childhood chemotherapy remains to be
clarified (Byrne et al., 1992). Ovarian dysfunction has been reported following
chemotherapy for standard risk ALL, but the chemotherapy protocols included
greater doses of alkylating agents (Quigley et al., 1989). The currents trends in
treatment of ALL are to increase the intensity of chemotherapy to improve survival
(Hann et al., 2000) .The late effects of the current treatment on reproductive function
can only be measured many years after completion of therapy and the risk for the
children currently undergoing chemotherapy without cranial irradiation may be
greater than the cohort we are currently following whose chemotherapy schedules
were less intense.
These data demonstrate that low dose cranial irradiation has an adverse effect on the
hypothalamic - pituitary - ovarian axis that may be progressive over time.
Apparently minor disturbances in LH secretion may have an effect on reproductive
potential: conception in normal women is more likely in cycles with greater LH
surges and higher luteal phase progesterone and oestradiol (Baird et al., 1999). Short
luteal phases are associated with reduced fertility and early miscarriage (Soules et al.,
1989). These data therefore indicate the importance of continuing assessment of
reproductive function in this cohort of survivors to detect effects of treatment that
may only become apparent may years later.
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CHAPTER 5: Depletion of the ovarian reserve in young
women following treatment for cancer in childhood:




Reproductive lifespan is determined by the number of primordial follicles and
treatment that results in atresia of follicles will accelerate the menopause (Gougeon
et al., 1994; Faddy et ah, 1992; Byrne et ah, 1992; Byrne et ah, 1999; Tilly et ah,
2002). Ovarian failure may occur immediately during or following treatment, or be
delayed by a variable period (Whitehead et ah, 1983; Wallace et ah, 1989a; 1993).
However for an individual, the risk cannot be readily predicted. With the arrival of
more intense, multi agent protocols the risk of depletion of primordial follicles may
increase.
The ability to predict a woman's reproductive lifespan would be of considerable
value to these long-term survivors of childhood cancer who may be counselled not to
delay childbearing. Current fertility prediction is limited. FSH is widely used in
clinical practice but shows considerable inter cycle variability (Sherman et ah, 1976;
Ahmed Ebbiary et ah, 1994; Wallach et ah, 1995) and reflects the sum of both
central hypothalamic drive and ovarian feedback. Direct products of the ovary,
including inhibin B and anti-Miillerian hormone (AMH) have been investigated as
markers of ovarian reserve (Seifer et ah, 1997; Tinkanen et ah, 1999; Creus et ah,
2000; Dumesic et ah, 2001); de Vet et ah, 2002), the latter showing particular
promise as a marker of the earliest growing follicles (Fanchin et ah, 2003b).
Biophysical measures including ovarian volume and antral follicle count (AFC) have
also been shown to correlate with reproductive potential (Tomas et ah, 1997; Syrop
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et al., 1999; Scheffer et al., 1999; Scheffer et al., 2003; Yong et al., 2003). AFC has
recently been demonstrated to be reduced in women who have survived childhood
leukaemia (Larsen et al., 2003), but no hormonal effects were detected in that group.
The assessment of reproductive potential is complicated in those women taking the
COCP. To evaluate ovarian function it has been necessary to stop the COCP, which
is inconvenient and impractical in young women relying on this method of
contraception. While it is likely that assessment of ovarian function during COCP
administration will remain less accurate than in women cycling spontaneously, it
would be of value to assess markers of ovarian function under these conditions.
The objective of this study was to investigate basal and stimulated hormone
production by the ovary in women who have survived cancer treatment as children to
detect and assess the degree of loss of the ovarian reserve. The relative value of
endocrine markers and ultrasound investigation was compared, both in women with




We recruited two groups of women from the long term oncology follow up clinic at
The Royal Hospital for Sick Children Edinburgh, and 2 groups of controls. Women
were suitable for recruitment into the study if they were older than 16 years, more
than 2 years since completion of therapy, had regular menstrual cycles (25 - 35 days)
or a history of return of menses post chemotherapy and were currently taking the
COCP (all containing 30pg ethinyl oestradiol). Women were excluded if they were
thought to have premature ovarian failure, defined by irregular or absent menses and
elevated gonadotrophins and currently on hormone replacement therapy, if they had
not received any chemotherapy or radiotherapy for their primary diagnosis or they
were thought not competent to give fully informed consent. Women without a
history of childhood cancer and with a history of regular menses were recruited as
controls. They were recruited by two methods: a) a poster campaign requested
women who had regular menses, were not on the OCP and aged 18-30 years and
were interested in taking part in a research study to contact the study coordinator and
b) by a special study module student (a research module during 4th year of
undergraduate training) who approached friends who were also undergraduates,
regarding participation in a research study. Women were suitable for recruitment into
the non-OCP group if they had not taken the OCP in the preceding 3 months. All
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participants gave written informed consent. Full ethical approval was given by the
local research ethics committee.
5.2.2.Study design
Women with spontaneous menstrual cycles attended during the early follicular phase
(day 3 to 5), and those taking the COCP during the third week of their pill cycle i.e.
between days 14 and 20. Venesection was performed and serum stored at -20°C for
subsequent assay. Transvaginal ultrasonography was used to determine ovarian
volume and the number of small antral follicles. All women were then administered
an injection of 225 IU recombinant FSH (rhFSH, Gonal F; Serono, Welwyn Garden
City, UK) subcutaneously, and returned 24 hours later for a further blood sample.
Patients taking the COCP had a further blood sample on day 7 of a subsequent pill-
free week for measurement of FSH to exclude occult ovarian failure: this was in the
normal range (<10IU/L) in all women.
5.2.3 Outcome measures
Immunoassays for FSH, E2, inhibin A, inhibin B and pro a-C inhibin forms and
ultrasound examinations were carried out as previously described (Yong et al.,
2003). All ultrasound all examinations were performed by the same investigator
using the same equipment (7Mhz probe, Toshiba Eccocee, Stirling, UK). AMH was
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measured in a single assay (AMH ELISA, Beckman Coulter, High Wycombe, UK),
intra assay CV 7%. Ovarian volume was calculated from 3 orthogonal diameters
using formula for a prolate ellipsoid (rc/6 x dl x d2 x d3) and mean volume of the
two ovaries calculated. AFC was determined as the mean of the number of follicles
2- 10 mm diameter in the two ovaries.
5.2.4 Statistical analysis
The day of onset of menses was defined as day 1 of the cycle. Hormonal data are
presented as mean and SEM, and were compared by Student's t test after log
transformation to correct for heterogeneity of variance. Ovarian volume and AFC




We recruited 10 women aged 24 (16 - 34) years [mean (range)] with regular
menstrual cycles (25-33 days) treated age 8 (3 - 12) years for cancer (table 4.1) and
11 controls(table 5.2) aged 23 (17-29) with regular menstrual cycles. We also
recruited 10 women aged 20 (17-29) years on the COCP treated age 8 (4-15) years
for cancer (table 5.3) and 10 controls aged 23 (22-26) years on the COCP (table 5.2).
The diagnosis and treatment schedules were as detailed in tables 5.1 and 5.3. All
women completed the study. There were no significant differences between age at
investigation or body mass index between the patient groups and between patients
and controls (data not shown). FSH administration resulted in a significant rise in
serum FSH concentrations at 24 hr in all four groups (P<0.01).
5.3.2 Women with regular menstrual cycles
The biochemical data of cancer survivors at baseline are shown in table 5.4 and 24
hours post injection of FSH in table 5.5. The biochemical data of the controls at
baseline are shown in table 5.6 and 24 hours post injection of FSH in table 5.7.
Among women with regular spontaneous menstrual cycles, cancer survivors had
significantly higher early follicular phase FSH compared to controls (7.5±1.4 vs
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Table 5.1 Clinical information on diagnosis and treatment of






1 4 34 ALL Chemo + CRT
2 11 16 Ewing's sarcoma Chemo + groin RT
3 12 29 ALL Chemo + CRT
4 11 27 Medulloblastoma Craniospinal RT
5 5 17 ALL Chemo + CRT
6 11 23 Rhabdomyosarcoma Chemo
7 2 20 ALL Chemo + CRT
8 8 24 Wilms tumour Chemo
9 12 18 Rhabdomyosarcoma Chemo + RT to face
10 4 18 NHL Stage 2 Chemo
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Table 5.2 Details of controls, women with regular menses not on
OCP and women on OCP
Subjects not on OCP Age at
investigation
Subjects on OCP Age at
investigation
1 17 1 22
2 29 2 22
3 24 3 24
4 23 4 23
5 21 5 22
6 25 6 23
7 22 7 23
8 21 8 26
9 21 9 22
10 26 10 22
11 28
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1 15 19 NHL stage 4 Chemo
2 5 21 ALL Chemo + CRT
3 3 17 ALL Chemo + CRT
4 2 17 ALL Chemo + CRT
5 5 16 Hodgkin's Chemo
6 9 29 Osteosarcoma Chemo
7 11 18 Hodgkin's disease Chemo
8 2 20 ALL Chemo + CRT
9 1 20 Wilms tumour stage 2 Chemo
10 9 28 ALL Chemo + CRT
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Table 5.4 Biochemical data of patients not on OCP at baseline
Pt no FSH AMH InhB Inh A Pro aC Oestradiol
U/L pmol/1 Pg/ml pg/ml pg/ml pmol/1
1 5.7 13.5 69.3 2.8 46.2 169
2 10.2 2.7 47.4 2.8 58 195
3 4 11.4 143.6 14.4 331 155
4 18.5 0.4 53.2 1.9 92.6 134
5 4.3 21.1 117.1 8.2 209.9 138
6 6.1 1.4 135.7 11.2 196.4 136
7 6.7 15.2 107.9 6.5 127.2 267
8 3 31.2 114.9 6.3 344.4 175
9 10.1 17.2 116.5 9.2 124.7 325
10 6.7 16.2 75.4 9 90.5 292
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Table 5.5 Biochemical data of patients not on OCP 24 hrs post
injection of FSH
Pt no FSH AMH InhB InhA Pro aC Oestradiol
U/L pmol/1 pg/ml pg/ml pg/ml pmol/1
1 7.5 14.1 157 15.3 87.3 331.8
2 10.9 2.8 87.5 13.2 102.1 194.1
3 5.6 11.4 392.8 53.1 402.8 407
4 20.3 0.4 79.6 5 121.9 187.2
5 9.6 21.4 231.8 22.2 295.6 492.5
6 14.9 1.5 216.2 28.9 239.9 530.3
7 7.4 15.5 275.6 20.9 200 484.1
8 4.9 31.4 164 14.8 299.7 349
9 12.6 19 220.1 22.4 223.6 617.7
10 7.2 19.4 216.6 26.6 219.3 314.4
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Table 5.6 Biochemical data of controls not on OCP at baseline
Pt no FSH AMH InhB Inh A Pro aC Oestradiol
U/L pmol/1 pg/ml pg/ml pg/ml pmol/1
1 4.1 15.2 114 13.7 188.6 203.7
2 4.1 27.1 93.4 10.2 149 151.9
3 4.2 24.3 154.1 17.5 230.6 229.4
4 5.6 16 83.6 2.7 231.1 102.4
5 4.1 14.8 39.8 1.9 153.4 167
6 5.1 32.1 106.4 13.7 157.8 272.3
7 3.8 33.6 99.2 7.9 186.2 157.8
8 4.8 18.4 80.7 1.9 186.4 110.8
9 2.4 24.3 80.3 4.7 241.2 109.7
10 3.3 17.7 6.9 124.8 146.4
11 4.5 7.5 32.4 4.3 218.8 145.3
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Table 5.7 Biochemical data of controls not on COCP 24 hrs post
injection of FSH
Pt no FSH AMH Inh B Inh A Pro aC Oestradiol
U/L pmol/1 Pg/ml pg/ml pg/ml pmol/1
1 7.4 13.4 218.9 36.3 276.5 322.2
2 9 29 209.2 30.6 222.3 466.1
3 7.7 19 297.7 43.9 257.9 796
4 8.2 18.1 136.2 12 251.3 164.4
5 5.1 16.4 198.6 11.2 175.8 201.1
6 6.4 30.1 188.8 39.1 297.9 4471.6
7 6.5 37.1 217.1 22.1 255.4 358.6
8 7.7 22.6 177.5 9.3 252.1 198.2
9 4.7 24.6 254.8 20 348.3 412.5
10 6.2 18.8 139.6 18.7 149.7 297.6
11 9.8 7.3 134.9 23 295.7 325.5
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Figure 5.1 Serum FSH, AMFI, inhibin A, B and proa-C and
oestradiol in women with spontaneous menstrual cycles. Controls
(open bars, n=11) and survivors of childhood cancer (filled bars,
n=10). Blood samples were taken in the early follicular phase
(basal) and 24 hr after administration of 225IU rhFSH (+FSH).
Mean ± SEM. * P <0.05 vs controls.
(a) FSH (b) AMH (c) Inhibin B
Basal ♦FSH Basal +FSH Basal +FSH
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4.2±0.3 IU/L, p = 0.02, figure 5.1a). AMH was significantly lower in cancer
survivors than controls (13.0±3.0 vs 21.0±3.4pmol/L, P <0.05, figure 5.1b) and was
unchanged following administration of FSH. There was no significant difference in
early follicular phase inhibin A, B, proa-C or oestradiol between cancer survivors
and controls, and all four hormones showed an increase in response to administration
of rhFSH (figure 5.1 c-f, p<0.01 in each case). However post-FSH concentrations
were also similar in cancer survivors and controls and there was no difference in
increment in inhibin B from baseline to stimulated response between the two groups.
USS data for the cancer survivors are shown in table 5.8 and for the controls in 5.9.
Ovarian volume was significantly smaller in cancer survivors than controls (3.0±0.5
vs 5.0±0.8 ml, P < 0.05, figure 5.2a). AFC was not significantly different between
patients and controls (8.4±1.4 vs 9.0±1.2, figure 5.2b).
5.3.3 Women taking COCP
The biochemical data of cancer survivors at baseline are shown in table 5.10 and 24
hours post injection of FSH in table 5.11. The biochemical data of the controls at
baseline are shown in table 5.12 and 24 hours post injection of FSH in table 5.13.
Basal FSH, oestradiol and inhibins were, as anticipated, low in both cancer survivors
and controls in the COCP groups (figure 5.3) with no significant differences in any
of the hormones between cancer survivors and controls. Inhibin A and B were
undetectable or very close to the limit of detection in both cancer survivors and
controls. Inhibin B showed a small increase which was significant (p=0.003) in the
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Table 5.8 USS data of patients not on COCP












Table 5.9 USS data of controls not on COCP













Figure 5.2 Average ovarian volume and antral follicle count in
controls (open bars) and survivors of childhood cancer (filled
bars), in women with spontaneous regular menstrual cycles and
during COCP administration. Mean ± SEM. * P <0.05 vs control








Spontaneous COCP Spontaneous COCP
cycles cycles
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Table 5.10 Biochemical data of patients on COCP at baseline
Pt no FSH AMH InhB InhA Pro aC Oestradiol
U/L pmol/1 pg/ml pg/ml pg/ml pmol/1
1 0.16 2.5 7.8 1.9 89.5
2 3.3 2.5 7.8 1.9 66.2 87.7
3 1.22 9.2 7.8 1.9 3.1 76.7
4 0.2 17.7 7.8 1.9 50.8 54.3
5 0.2 0.4 7.8 1.9 124 55.8
6 0.8 4.3 7.8 1.9 3.1 94
7 0.4
8 2.5 17.7 7.8 1.9 50.4 71.2
9 0.5 25.1 2.98 158.4
10 0.5 28.7 7.8 1.9 44.3 110.1
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Table 5.11 Biochemical data of patients on COCP 24 hrs post
injection of FSH
Pt no FSH AMH InhB Inh A Pro aC Oestradiol
U/L pmol/1 pg/ml pg/ml pg/ml pmol/1
1 4.2 4.9 7.8 1.9 89.8
2 8.1 17.7 125 4.6 71.6 78.5
3 5.6 9.9 7.8 1.9 134.4 271.6
4 5.1 17.1 49.8 1.9 75.4 68.3
5 5.1 0.4 7.8 1.9 77.7 66.1
6 3.3 6 7.8 1.9 75.4 103.9
7
8 4 21.5 72.6 1.9 112 98.4
9 4.4 193.8 15.1 218.7 141.7
10 1.9 28.6 7.8 1.9 3.1 132.5
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Table 5.12 Biochemical data of controls on COCP at baseline
Pi no FSH AMH InhB InhA Pro aC Oestradiol
U/L pmol/1 pg/ml pg/ml pg/ml pmol/1
1 2.3 9 7.8 1.9 89 121.8
2 0.1 12.5 7.8 1.9 72.7 139.8
3 2.7 22 7.8 1.9 171 97.3
4 0.5 5.5 7.8 1.9 336.6 79.6
5 0.1 21.3 7.8 1.9 286.9 178
6 0.3 7.2 7.8 1.9 75.2 65.7
7 0.3 8 7.8 1.9 105 87.3
8 0.6 12.2 27.3 1.9 51.5 97.3
9 0.6 10.2 7.8 1.9 77.4 76
10 3.7 12.2 7.8 1.9 94.1 111.9
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Table 5.13 Biochemical data of controls on COCP 24 hrs post
injection of FSH
Pt no FSH AMH Inh B Inh A Pro aC Oestradiol
U/L pmol/1 Pg/ml Pg/ml pg/ml pmol/1
1 5.7 9.2 92.6 3.7 160.1 235.6
2 4.3 9.2 28.4 1.9 128.1 101.3
3 5.8 23.6 37.6 1.9 80.6 139.8
4 3.3 5.4 35.2 1.9 182.5 85.5
5 2.3 22.6 132.2 4.5 233.6 198.9
6 3.3 9.1 33.3 1.9 75.9 78.9
7 3.1 8.9 84.1 1.9 101.6 62.4
8 3.6 13.4 33.6 1.9 79.6 78.9
9 4.5 10 28.2 1.9 77.4 88.8
10 9.4 13 93.9 5.9 243.9 216.9
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Figure 5.3 Serum FSH, AMH, irihibin A, B and proa-C and
oestradiol in women on COCP. Controls (open bars, n=10) and
survivors of childhood cancer (filled bars, n=10). Blood samples
were taken in the third week of a COCP cycle before (basal) and
24 hr after administration of 225IU rhFSH (+FSPI). Mean ± SEM.
P <0.05 vs basal.
Inhibin B
Basal ♦FSH Basal ♦FSH Basal ♦FSH
pg/ml
Basal ♦FSH Basal +FSH Basal ♦FSH
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control group but not in the cancer survivor group. However analysis of individual
inhibin B responses identified six cancer survivors with undetectable inhibin B pre-
FSH (< 7.8 pg/ml) in whom inhibin B remained undetectable after FSH stimulation
whereas control women, who also had undetectable inhibin B concentrations pre-
FSH, all showed a rise of greater than 20 pg/ml in response to FSH. Inhibin A
remained undetectable in all except three controls and two cancer survivors who
showed a response, and proa-C and AMH were unchanged. Serum oestradiol
showed a small but not statistically significant increase in response to FSH
administration in both groups, with no differences between groups.
USS data for the cancer survivors are shown in table 5.14 and the controls table 5.15.
Ovarian volumes were significantly lower in both COCP cancer survivors and
controls compared to the groups with spontaneous ovarian activity (1.7±0.3 vs
3.0±0.5 ml, P<0.05 and 2.1±0.2 vs 5.0±0.8 ml, p=0.002 respectively, figure 5.2a).
There were no significant differences in ovarian volume between COCP-taking
patients and controls. AFC however was significantly lower in COCP-taking cancer
survivors than controls (4.2+0.8 vs 7.2±0.8, P = 0.02, figure 5.2b). COCP-taking
cancer survivors who showed no inhibin B response to FSH had slightly lower AFC
than those who did respond (3.6 vs 4.6) but these differences did not reach statistical
significance.
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Table 5.14 USS data of patients on COCP












Table 5.15 USS data of controls on COCP













Fertility is a major concern among women who have survived cancer during
childhood. Some women may develop an early menopause, but others may progress
through puberty normally and have regular menstrual cycles with normal endocrine
profiles. As the agents used to treat the malignancies of childhood will destroy a
greater or lesser number of ovarian primordial follicles, it is of value to be able to
assess accurately the effect of treatment on the ovarian reserve even in those women
with apparently normal ovarian function. This has proved difficult because of the
low metabolic activity of primordial follicles, and the number of growing follicles,
particularly the FSH-dependent small antral follicles, has been widely used as a
substitute as this number is believed to reflect the number of primordial follicles
(Gougeon et al., 1994). Early data from autopsy specimens of children with
leukaemia directly demonstrated a reduction in antral follicle number following
chemotherapy (Himelstein-Braw et al., 1978). In this study we have demonstrated
both hormonal and biophysical evidence of partial loss of the ovarian reserve in
young cancer survivors with regular cycles.
Two hormonal differences were detected between cancer survivors and controls.
Firstly, early follicular FS1T was significantly elevated, although was high in only
one patient (18.5 IU/L, others all <10.2 IU/L). However there was a striking fall in
serum AMH concentrations, while the other direct products of the ovary, oestradiol
and the inhibins A, B and pro-aC, were unchanged. AMH is produced by the
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granulosa cells of small growing follicles (Baarends et al., 1995) and is involved in
the regulation of primordial follicle recruitment (Durlinger et al., 1999). It has
recently been suggested to be a marker of ovarian ageing (de Vet et al., 2002). The
circulating concentration shows little fluctuation over the menstrual cycle (Cook et
al., 2000) but is a relatively good predictor of the number of small FSH-sensitive
follicles and thus of the number of oocytes recovered following controlled ovarian
stimulation (van Rooij et al., 2002; Seifer et al., 2002; Fanchin et al., 2003b).
Consistent with previous reports, serum AMH was unchanged by administration of a
single dose of FSH. The present data are thus consistent with a partial depletion of
the follicular reserve in these patients and is the first demonstration of a fall in an
ovarian hormone in such cancer survivors with regular menstrual cycles.
Ovarian volume but not AFC was also reduced in the cancer survivors compared to
controls. Both ovarian volume and AFC are indirect markers of the ovarian reserve
(Tomas et al., 1997; Syrop et al., 1999; Scheffer et al, 1999, 2003; Yong et al.,
2003), and have been reported to be reduced in female survivors of childhood cancer
(Larsen et al., 2003). Inhibin B, a product of these follicles, was also normal. It has
recently been demonstrated that the value of inhibin B as a measure of the ovarian
reserve is greatly increased following administration of a single dose of FSH to
stimulate granulosa cell function in small healthy follicles (Yong et al., 2003). While
these results show the expected increase in inhibin B following FSH administration,
there remained no difference between patients and controls. Together with the AFC
results, these data are consistent with these cancer survivors having a near-normal
compliment of small antral follicles. The discrepancy between these normal results
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and the clearly reduced AMH data may illustrate the problems inherent in trying to
assess the number of primordial follicles present using only indirect means. As
AMH is the product of the smallest growing follicles, it may more accurately reflect
the ovarian reserve than AFC and basal and stimulated inhibin B. The latter two
markers reflect the number of FSH-sensitive small antral follicles and therefore show
relationships to the number of oocytes recovered following controlled ovarian
stimulation, but it appears they are unable to reflect the reduced ovarian reserve
exhibited by the cancer survivors investigated here.
Groups of cancer survivors and controls taking the COCP were also investigated in
this study. The ability to carry out accurate assessment of the ovarian reserve under
such conditions would be of great practical value in the light of the high prevalence
of oral contraceptive use among young women. Assessment under
hypogonadotrophic conditions might also be advantageous: GnRH analogue-induced
hypogonadotrophism with subsequent FSH stimulation has been shown to greatly
increase the correlation between inhibin B and oocyte recovery following controlled
ovarian stimulation (Yong et al., 2003). As with the spontaneously cycling groups,
cancer survivors taking the COCP showed both hormonal and biophysical
differences from the control group although the differences were in distinct measures
of ovarian function. During COCP administration, inhibin B was suppressed to
undetectable concentrations in both cancer survivors and controls. In response to
FSH administration, the two groups showed similar responses overall, but analysis of
individual responses showed that whereas all controls showed a response to FSH,
only 6/10 cancer survivors showed a response, inhibin B remaining undetectable in
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the others. AFC was lower in women taking the COCP (significantly so for the
cancer survivor groups), but there was also a significant difference in AFC between
COCP-taking cancer survivors and COCP-taking controls. Thus, in contrast to the
spontaneously cycling groups, during COCP administration there were differences
between cancer survivors and controls in AFC and inhibin B. These results again
suggest that cancer survivors show a degree of depletion of the ovarian reserve, and
under conditions of hypogonadotrophism, this is reflected in the number of FSH-
sensitive antral follicles. As the degree of loss of the ovarian reserve is modest, it
may be that under normal conditions the larger number of growing follicles has
obscured our ability to detect differences between the groups.
Ovarian volume and serum AMH were however not significantly different between
COCP-taking cancer survivors and controls. Both these markers were significantly
reduced in the COCP controls compared to the spontaneously cycling controls,
indeed to values similar to those found in the spontaneously cycling cancer
survivors. It appears likely that the effect of the COCP has obscured the value of
these markers of the ovarian reserve. Ovarian volume, AFC, inhibin B and AMH are
all to greater or lesser extents markers of the ovarian reserve. They are however
both indirect and while inter-related reflect slightly different aspects of ovarian
function. The present results further illustrate the relationships between them under
different conditions, and confirm the need for a range of markers for a full
assessment of the ovarian reserve.
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Some chemotherapy agents are known to be more gonadotoxic than others (Mackie
et al, 1996; Whitehead et al., 1983). In particular, alkylating agents are recognised to
carry a significant risk of premature ovarian failure. Greater than half the group of
cancer survivors (ALL and Wilms' tumour survivors) have received treatment
believed to have little or no ovarian toxicity (Wallace et al., 1993) although
craniospinal irradiation may have indirect adverse effects on ovarian function (Bath
et al., 2001). However, of the six patients taking the COCP who showed no inhibin B
response to FSH, three had been treated for ALL. Analysis is limited by the small
number of patients treated for a variety of primary diagnoses with different
chemotherapy regimens, but these data show even these therapies are associated with
a detectable loss of ovarian reserve.
In conclusion, survivors of childhood cancer were demonstrated to have suffered a
depletion of the ovarian reserve despite maintaining regular menstrual cycles. Serum
AMH concentrations and measurement of ovarian volume by transvaginal ultrasound
scan were found to be the clearest indicators of this. Evidence of a similar effect was
also detected despite COCP administration using different markers. Regular
menstrual cycles and normal early follicular phase FSH do not therefore confirm the
absence of damage to the ovary, and such patients should be advised accordingly.
Long term follow up of these patients is necessary to further evaluate ovarian
function and definitively correlate these indirect markers of the ovarian reserve
investigated here with true reproductive lifespan. Prospective systematic collection
of data will also, in the future, allow a more accurate prediction of reproductive
potential.
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CHAPTER 6: Ovarian and uterine Characteristics after
total body irradiation in childhood and adolescence:
Response to sex steroid replacement
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6.1 Introduction
The majority of children treated for acute leukaemia are cured with intensive
chemotherapy and will be fertile (Nicholson et al., 1993; Wallace et al., 1991;
Wallace et al., 1993). For patients with high risk or relapsed disease the prospect of
cure has been improved with the increasing success of BMT with TBI as the
conditioning treatment (Chessels., 1998).
The aim of this study was to investigate ovarian function and uterine characteristics
in long term survivors following TBI. Uterine size, blood flow and endometrial
thickness were determined by ultrasonography in women with premature ovarian
failure in response to exogenous sex steroid replacement and in response to
endogenous sex steroid production in women with spontaneous ovarian function.
The events of implantation and placentation will reflect prevailing endometrial




Eight post pubertal women who had been treated with total body irradiation as
children/ adolescents were studied (Group A). They were recruited from a total of
nine women treated with TBI in paediatric centres in Scotland in long term
remission. The one patient not recruited was receiving treatment for Hepatitis C.
They were all treated with a total of 14.4 Gray in 8 fractions over 3 days, in first or
second remission for leukaemia. The chemotherapy protocols were the MRC ALL or
AML trial according to the time of primary diagnosis. Those in second remission had
all previously received cranial irradiation. Of the 8 patients in group A, 5 were
available for further study. Two comparison groups were studied; groups B and C.
Women in group B (n = 12) were treated with chemotherapy and cranial irradiation
and were in first remission following treatment with standard UK protocols for acute
leukaemia (Burnett et al., 1997). They were recruited from the late effects clinic at
the Royal Hospital for Sick Children, Edinburgh. Group C (n = 5) were healthy
controls with regular menstrual cycles and no history of childhood malignancy. They
were recruited following a poster campaign to recruit healthy young women with
regular menstrual cycles, not on the OCP. The age at treatment and age at assessment
for each group are shown in table 6.1.
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Table 6.1. Age at treatment and age at assessment for each
group [median(range)]
age at treatment age at assessment
Group A (n=8)
Group B(n=12)
11.5 (5.9 - 15.1) years
6.7 (3.8 - 13.5) years
Group C(n=5)
17.1 (15.4-21.5) years
21.8 (15.8 - 32.8) years
25.2 (24.1 - 27.1) years
Table 6.2. Details of physiological sex steroid replacement
regimen.
Week 1 Week 2 Week 3 Week 4
Oestradiol 100mcg/24hrs 150mcg/24hrs 150 mcg/24 hrs 150 mcg/24 hrs
Progesterone 200 mg/12 hrs 200 mg/12 hrs
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6.2.2 Study design
Each woman had an initial assessment to determine pubertal development, date of
menarche, regularity ofmenses and, where appropriate, age at commencement of sex
steroid replacement. Spontaneous ovarian function was assessed in women taking
sex steroid replacement (SSR) after discontinuing that treatment for 4 weeks.
Ovarian failure was confirmed by raised serum gonadotrophins, low serum oestradiol
and absent menses.
Subjects with ovarian failure then commenced a physiological regimen of sex steroid
replacement administered as transdermal oestradiol patches (Estraderm TTS,
Novartis, Horsham, UK) and vaginal progesterone pessaries (Cyclogest, Shire
Pharmaceuticals Ltd, Andover, UK) as detailed in table 6.2. This regimen has
previously been shown to produce physiological levels of sex steroid replacement in
women with premature ovarian failure (Critchley et al., 1990). The pSSR regimen
was continued for 3 cycles, and detailed assessment was undertaken during the third
cycle. Alternate day urine samples were collected which were stored at -20 °C until
assayed for LH, oestrone and pregnandiol. Subjects were assessed at times in the
cycle equivalent to early follicular (day 3 - 5), mid-late follicular (day 9-12) and
mid luteal phase (day 22 - 24) by ultrasound scan and hormone measurements. In
sexually active women consent was sought for collection of an endometrial biopsy in
the simulated mid-luteal phase.
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In women with spontaneous cycles, ovarian function was assessed for 3 cycles by
collection of a daily urine sample. Measurement of LH was used to accurately time
the mid luteal assessment and oestrone and pregnandiol were measured to confirm
ovulation. Subjects underwent detailed assessment of ovarian and uterine function
during the third cycle as described for women on pSSR at early follicular, mid
follicular and mid luteal stages of the cycle.
Ethical approval was given by the local ethics committee and informed consent was
obtained from all women in the study.
6.2.3 Ultrasound scan
All ultrasound examinations were performed by one of two consultant radiologists
trained in gynaecological scanning using a Hitachi EUB 555. Scans were performed
transvaginal^ (6.5 MHz transducer) in sexually active women and transabdominally
(3.5 MHz transducer) in those who were not. The measurements recorded were
uterine volume, blood supply and endometrial thickness and ovarian volume and the
presence and size of follicles. Uterine volume was calculated from the three
dimensions, length (di), measured from the fundus to the external os, the transverse
diameter (d2) and the antero-posterior diameter (d3) and by assuming the forms to be
ellipsoid, using the formula for a prolate ellipsoid (dixd2xd3) x 0.523. The
endometrial thickness was measured on a sagittal section, the maximum antero¬
posterior diameter was measured for both layers. Uterine artery blood flow was
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evaluated using colour and pulsed flow doppler. The PI was used to express blood
flow impedance distal to the point of sampling. The PI was derived from the flow
velocity wave form, according to the formula PI = A - B/mean, where A is peak
systolic Doppler shift frequency, B is the end diastolic shift frequency and the mean
is the mean maximum Doppler shift frequency over the cardiac cycle (Taylor et al.,
1985; Steer et al., 1990). The ovarian volume was measured in three orthogonal
diameters and the same formula for a prolate ellipsoid applied.
6.2.4 Endometrial morphology
In sexually active women an endometrial biopsy was collected in the mid luteal
phase (natural or simulated). The samples were conducted with a Pipelle suction
curette (Laboratoire CCD, Paris, France) and endometrium placed in neutral buffered
formalin prior to embedding in paraffin. Subsequently 5 micron sections were cut
from the paraffin blocks for histological examination and immunohistochemical
detection of both ER and PgR (Critchley et al., 1998; Snijders et al., 1992)
6.2.5 Hormone analyses
Urinary oestrone and pregnandiol were measured using an "in house" ELISA using
HRP-conjugate as label and solid-phase second antibody separation (for oestrone CV
< 4%; for pregnandiol CV <13%). Urinary LH was measured by a two-site IRMA
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(Serono MAIA clone) (CV < 12%). Urinary hormone concentrations were corrected
for creatinine concentration. Serum oestradiol was measured by competitive
immunoassay using the Boehringer Mannheim Elecsys (Mannheim, Germany).
Progesterone, FSH and LH were measured by microparticle enzyme immunoassay
on the Abbott Axsym (Chicago, Illinois). Inhibin B was measured using a two-site
ELISA using plates coated with specific monoclonal antibodies to the BB subunit of
inhibin B as previously described (Groome et al., 1996). Assay sensitivity was
7.8pg/ml, intra- and inter-plate CVs were 10.6% and 11.4% respectively.
6.2.6 Statistical analysis
The ultrasound and serum assay results were not normally distributed and therefore
non parametric tests was used to analyse the data. The data are therefore presented as
medians, ranges and interquartile ranges. For within group comparisons we used the
Wilcoxon signed ranks test. For between group comparisons we used the Wilcoxon
rank sum test. To investigate the relationship between non parametric variables we




Six of the 8 women in group A (treated with TBI) had absent ovarian function
requiring sex steroid replacement and all had required sex steroid treatment for
pubertal induction. Two patients treated pre pubertally had progressed spontaneously
through puberty without SSR, although their cycles were irregular. The timing of
treatment according to pubertal stage is as shown in table 6.3. Of this group, 4 with
ovarian failure and 1 with spontaneous menses underwent further detailed
investigation.
All 12 women in group B (table 6.4) and all controls (group C) had progressed
spontaneously through puberty and had regular menses. There was no significant
difference between these 2 groups in ultrasound scan data, blood results or
endometrial biopsy and their data were therefore combined as the comparison group.
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Table 6.3. Patient details of group A.
Pt no diagnosis age at breast stage age at ovarian full study
TBI at TBI assessment function data
1 ALL 15.1 StV 19 F N
2 CML 12.7 StV 21.5 F Y
3 AML 12.5 StV 16.7 F Y
4 ALL 13.6 St IV 17.2 F Y
5 ALL 10.5 St I 16.0 F N
6 ALL 7.9 St I 15.5 NF Y
7 ALL 5.9 St I 15.6 NF N
8 ALL 4.9 St I 14.1 F Y
Ovarian function: F, failed ; NF, not failed.
Participation in full study: Y, yes; N, no.
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Table 6.4 Patient details of Group B




1 ALL 3.2 16.3
2 ALL 3.9 30.1
3 ALL 1.9 22
4 ALL 5.5 17.3
5 ALL 2.1 19.5
6 ALL 11.2 32.6
7 ALL 3.2 16.8
8 ALL 6 23.2
9 ALL 10 17.3
10 ALL 7.2 23.7
11 ALL 2.2 16
12 ALL 13.1 24.3
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6.3.2 Ovarian function
Four women with ovarian failure following TBI were assessed after discontinuing
hormone replacement therapy 4 weeks previously. Gonadotrophins were elevated,
oestradiol was low and inhibin B was undetectable confirming ovarian failure (tables
6.5 and 6.6). On USS ovarian structures were detectable in only 2 of the 4 patients
(0.5, 0.7 mis), and were significantly smaller than those in Groups B and C [5.1 (2.48
- 8.48mls)] [median (range)](p < 0.05). During the third cycle of pSSR hormone
concentrations were determined on days 3-5 (table 6.7) and 22-24 (table 6.8).
Gonadotrophins were greatly reduced towards or into the normal range, and
oestradiol and progesterone concentrations were also normalised (table 6.5).
One patient (patient no 7) with preserved ovarian function but irregular menses
following TBI showed moderately elevated gonadotrophins, in the follicular phase,
FSH 26 U/L and LH 8.9 U/L, with undetectable inhibin B consistent with incipient
ovarian failure. Following ovulation (confirmed on urine LH surge) serum
gonadotrophins, oestradiol and progesterone were within the normal range for the
mid luteal phase. The volume of each ovary was 0.8 and 0.6 mis.
For the 4 women with ovarian failure, urine hormone measurements during the third
cycle confirmed that pSSR treatment resulted in urinary oestrone and pregnandiol
concentrations not significantly different from the quoted reference range. In 2 of the
4 patients in group A with ovarian failure a mid cycle urinary LH surge was
demonstrated indicating normal response of the hypothalamic-pituitary-gonadal axis.
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Table 6.5 Biochemical data of Group A at baseline
Pt
k




2 108 55 51 <7.8
3 79 67.5 <37 <7.8
4 88 47.7 28 <7.8
8 107 45.7 <37 <7.8
Table 6.6. Endocrinology of patients with ovarian failure (n=4)
[median(range)].
Baseline Cycle 3,day 3-5 Cycle 3,day 22 - 24
FSH U/l 97 (88 - 108) 10 (5.3-10.9) 6.3 (3.8-10.9)
LHU/1 51 (45 -67) 2.8 (1-4.1) 1.1 (1-1.3)
Oestradiol pmol/1 14 (0- 51) 422 (136- 1736) 407 (215 -965)
Progesterone nmol/1 0 0 18.3(12.6-29.4)
Inhibin B pg/ml <7 .8 <7.8 <7.8
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Table 6.7 Biochemical data of group A during 3rd month of pSSR
on day 3-5 or day 3-5 of spontaneous cycle (pt 6).




2 9.9 2 433 <7.8
3 10.3 4.1 417 <7.8
4 10.9 1.0 57 <7.8
6 26 8.9 38
8 5.3 3.6 1736 <7.8
Table 6.8 Biochemical data of Group A during third month of
pSSR on day 22-24 or day 22-24 of spontaneous cycle (pt 6)
Pt FSH U/L LH U/L Oestradiol
pmol/1
Progesterone
2 6.6 1.1 313 16.5
3 3.9 1.3 965 12.6
4 10.9 1.0 136 29.4
6 4 3 243 15.7
8 3.8 1 215 28.1
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Women with spontaneous ovarian function were confirmed to be ovulating by the
presence of an urinary LH surge followed by a rise in urinary pregnandiol.
6.3.3 Uterine characteristics post TBI
Four women in group A were confirmed to have ovarian failure after discontinuing
their standard SSR for 4 weeks. Baseline assessment, 4 weeks after discontinuing
their standard SSR, demonstrated uterine volume significantly reduced compared to
Groups B and C (p < 0.01), undetectable uterine blood flow in 3 of the 4 women and
no significant endometrial tissue (table 6.9). Following 3 cycles of pSSR they were
reassessed (tables 6.10 and 6.11). There was an increase in uterine volume from 6.5
(1.7 - 12.7) ml [median (range)] at baseline to 16.5 (8.3 - 27.4) ml during the third
cycle (table 6.12). The increase in uterine volume from baseline for each patient is
shown in Fig. 6.1 and demonstrates that each patient had a sustained increase in
uterine volume through the 3rd cycle of pSSR. Uterine volume measured during third
cycle showed a significant correlation with age at TBI (p< 0.05) (fig 6.2).
Endometrial thickness also increased from 0 (0 - 2.6) mm at baseline to 5.2 (3.5 -
7.5) mm during the mid luteal phase of the third cycle (table 6.12). Uterine artery
blood flow, not detectable in 3 of the 4 patients at baseline, was detected in all
patients during the third month of pSSR at which time uterine pulsatility index was
within the normal range at 2.6 (1.9 - 3.4) (table 6.10).
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2 12.7 3.24 2.6 0.5
3 10.2 Not seen 0 Not seen
4 1.7 Not seen 0 Not seen
8 2.8 Absent end
diastolic flow
0 0.7
Table 6.10 USS data of women in group A during 3rd month of









2 17.4 2.64 5.4 Not seen
3 27.4 1.83 4 Not seen
4 15.5 2.73 0 Not seen
6 11.6 3.76 3 0.51
8 8.3 2.63 3 Not seen
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Table 6.11 USS data of women in group A during 3rd month of
pSSR, day 22-24 or during spontaneous cycle day 22-24 (pt 6)
Pt Uterine Pulsatility Endometrial Ovarian
volume mis index (left) thickness mm volume mis
2 18.6 3.09 5.9 Not seen
3 25.9 3.22 5.5 Not seen
4 17.5 3.34 4.8 Not seen
6 12.4 1.46 8 1.1
8 7 2.64 3.5 Not seen
Table 6.12. Uterine volume and endometrial thickness of women
with ovarian failure following treatment with TBI (n = 4) at baseline
and after exposure to pSSR [median(range)].
Baseline 3rd cycle of pSSR
Uterine volume (mis) 6.8(1.7-12.7) 17.3 (7.0-25.9)
Endometrial thickness (mms) 0 (0 - 2.6) 5.4 (3.5 - 7.5)
day 22-24
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Figure 6.1 Change in uterine volume in patients in Group A from
baseline compared to 3rd cycle of pSSR. Patients no 2, 3 and 4
were treated peri/post pubertally. Patient no 8 was treated pre
pubertally. Pt no 2 = □ , Pt no 3 = O , Pt no 4 = o ,Pt no 8 = ▲.
baseline D 3-5 D 9-11 D 22-24
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Figure 6.2 Correlation between uterine volume during 3rd cycle of
pSSR (n = 4) or spontaneous ovarian function (n = 1) and age at
irradiation (p<0.05).
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6.3.4 Comparison of Groups A, B and C
The data from women in Group A following exposure to physiological sex steroid
serum concentrations (pSSR for 3 cycles (n=4) or endogenous production (n=T,
patient no 7)) were compared to that from women in Groups B (table 6.13) and C
(table 6.14).
The uterine volume of women in group A [15.5 (8.3 - 27.4) ml] remained
significantly smaller than in groups B and C [38.9 (26.8 - 64.0) ml] (p< 0.01) (table
6.15). Endometrial thickness increased through the cycle in all women studied and
was not significantly different between the 2 groups. During the luteal phase the
endometrial thickness in group A (table 6.11) was 5.5 (3.5 - 8) mm and in groups B
(table 6.16) and C (table 6.17) 7.8 (6.6 -12) mm (table 6.15). There was a significant
correlation between urine oestrone concentrations and endometrial thickness in those
on pSSR (p < 0.05). There was no significant difference in uterine artery pulsatility
index during third cycle between group A [PI = 2.4 (1.9 - 3.4)] and groups B and C
[PI = 2.1 (1.5-3.1)].
6.3.5 Endometrial morphology
An endometrial biopsy in the simulated mid luteal phase was obtained from patient
no 2. Histological examination showed convoluted glands in an oedematous stroma
with spiral arteriole formation. The histology and immunohistochemical distribution
of oestrogen and progesterone receptors displayed features consistent with secretory
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phase endometrium. In the early secretory phase ER immunoreactivity declined more
markedly in the stromal cells, whereas ER expression in the glands decreased more
gradually. Progesterone receptor expression declined in the glandular epithelium.
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1 40.6 3.14 4 1.54 3.4
2 35.5 2.04 1.4 2.02 3.1
3 64 1.67 7 3.26 7.5
4 33.8 2.39 4.5 4.55 3.1
5 57.9 2.19 3.6 8.6 3.3
6 46.8 2.59 6 8.8 5
7 38.9 2.51 1.4 7.7 9.2
8 26.8 2.77 7.6 3.9 3.4
9 26.9 2.23 1.3 2.7 Not seen
10 47.4 2.32 1.4 4.9 5.6
11 28.1 2.58 2.5 6.7 5.7
12 51.5 3.17 3.5 3.8 6.1
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1 48.3 2.98 1.4 3.5 4.8
2 36.4 1.65 3 3.5 6.6
3 53.2 1.85 5.3 8 6
4 46.4 1.45 5.8 9.2 8.7
5 39.2 2.47 4.5 6.8 7.1
Table 6.15. Uterine volume and endometrial thickness of women
in Group A (n = 5) during 3rd cycle compared to Groups B and C
(n = 17). *p < 0.01; ** p > 0.05
Group A Groups B and C
uterine volume (mis) 16.3 (7.0-25.9)* 41.5 (28.1 - 57.9)
endometrial thickness (mm) 5.9 (3.5 - 8.0)** 8.7 (6.6 - 12.4)
day 22 - 24
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Table 6.16 USS data of women in group B day 22-24














Table 6.17 USS data of women in Group C Day 22-24








Following TBI in childhood and adolescence we have confirmed that the majority of
women have permanent ovarian failure (Ogilvey-Stuart et al., 1992; Sanders et al.,
1996). This is however the first study to assess the uterine characteristics and the
response to pSSR after TBI in young women. At baseline all these women had a
small uterus, with poor blood flow and absent endometrium. Following physiological
sex steroid replacement for 3 months all measures of uterine function improved such
that there was no significant difference in uterine blood flow and endometrial
thickness from the comparison group. Uterine volume, although increased with
pSSR, remained significantly less than the comparison group.
TBI carries a significant risk of permanent ovarian failure. Although our numbers are
small, the risk appears greatest for girls treated post pubertally, which is consistent
with reports from other groups (Sarafouglou et al., 1997; Sanders et al., 1996;
Sanders et al., 1986; Leiper et al., 1987). In woman treated pre pubertally with TBI
ovarian function may be preserved but there remains a risk of early ovarian failure
(Byrne et al., 1992). The concentration of inhibin B in the early follicular phase
declines with age, suggesting that it may reflect the follicular reserve. In our women
with radiation induced ovarian failure inhibin B was undetectable, as would be
predicted. However in the patient with preserved ovarian function, inhibin B was
also undetectable in the early follicular phase of an apparently ovulatory cycle. Our
findings are consistent with the suggestion that inhibin B may be a valuable measure
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of the follicular reserve in women with iatrogenic, and possibly also pathological or
physiological, incipient ovarian failure (Klein et al., 1996).
The basis for poor uterine function following radiotherapy is unknown. Uterine
blood supply, endometrial function and uterine distensibility have all been implicated
(Hawkins et al., 1989). In the present study, women with ovarian failure after TBI
showed an increase in uterine volume, blood supply and endometrial thickness after
3 cycles of pSSR. A previous study (Critchley et al., 1992) employing this regimen
of pSSR did not demonstrate any significant change in uterine characteristics in
women irradiated in childhood. There are a number of important differences between
this study and the present study. The patients in the study by Critchley et al were
treated at a younger age, with whole abdominal irradiation, with 20 - 30 Gy and they
were assessed during only one cycle of pSSR. It may be that further exposure to
pSSR would improve uterine characteristics. Wallace et al (1989b) reported poor
uterine function for women who had preserved ovarian function following whole
abdominal irradiation, with all pregnancies ending in mid trimester miscarriage. For
the women treated with TBI it is uncertain whether there would be a further
improvement in uterine characteristics with longer exposure to pSSR than the 3
months investigated here. Assessment of uterine distensibility was not undertaken in
this study, but may provide further information as to degree of damage to the uterus
and the potential to support a pregnancy.
We have shown that uterine volume increased with exposure to pSSR although
remained significantly smaller than the comparison group. There was a significant
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positive correlation between uterine volume when exposed to pSSR and age at
irradiation. The younger the women at TBI, the smaller the uterus which might
explain the report of Sanders et al., (1996) that all pregnancies among females who
received TBI while pre pubertal resulted in spontaneous miscarriage. Pre pubertal
treatment with TBI appears to increase the chance of preservation of ovarian function
but the prospect of a successful pregnancy outcome for these women is more
uncertain. Women treated post pubertally were noted to have a larger uterine volume
and viable pregnancies have been reported for this group. However there is an
increased risk of premature labour and low birth weight which is not seen in girls
treated with myelo-ablative doses of chemotherapy (Sanders et al., 1996).
Uterine blood flow may be assessed by the uterine artery pulsatility index which
varies through the menstrual cycle (with times of greatest impedance to flow during
menstruation, and least impedance at times of possible implantation (Steer et al.,
1990)). In the absence of SSR, uterine artery blood flow was undetectable in 3 of the
4 women treated with TBI, but with pSSR the pulsatility index was observed to be
within the normal range. The uterine artery therefore remains responsive to sex
steroids following irradiation but it is not clear whether this observed improvement
in uterine blood flow will be sufficient to sustain a successful pregnancy.
Appropriate endometrial development is crucial to the success of implantation and
placentation. The endometrium fails to respond to sex steroid replacement only in
exceptional cases, for example following pelvic radiotherapy (Critchley et al., 1993;
Li et al., 1991; Sauer et al., 1997). With the current regimen there was a correlation
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between endometrial thickness and urine oestrone concentration. Therefore optimum
levels of serum oestradiol should be achieved for maximal endometrial response.
This may be achieved with serial plasma monitoring and increasing transdermal
oestradiol replacement. The thickness may also correlate with age at treatment, those
with smaller uterine volume treated at a younger age may have reduced thickness.
Our numbers were insufficient to investigate this relation. Embryo transfer in certain
in vitro fertilisation centres is considered when endometrial thickness is > 6 mm. We
have not speculated on thickness that would be suitable for IVF, as we do not feel
this is the only item to be considered. Uterine size is also likely to be a limiting step
to successful IVF for these women. In our study we obtained an endometrial sample
from a patient who had been treated with TBI post puberty. This demonstrated
normal luteal phase histology (Noyes et al., 1950) and a similar expression of
oestrogen and progesterone receptors to that found in normal tissue (Snijders et al.,
1992; Critchley et al., 1993; Critchley at al., 1998).
In considering donor oocytes for such women with ovarian failure, uterine function
will be important. The uterine response to physiological sex steroid serum
concentrations may be an encouraging guide, on an individual basis, if whether it is
sensible to pursue assisted reproduction with donor oocytes as a method of achieving
fertility. The validity of such measures as prognostic tests remains to be
prospectively demonstrated.
In conclusion, premature ovarian failure after TBI is common and risk relates to age
at treatment. Further, these data indicate that a physiological regimen of sex steroid
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replacement will improve uterine characteristics. These are encouraging observations
for a group of young women who may in the future be candidates for assisted
reproductive technologies. Uncertainty however still remains about the most
appropriate dose and delivery route for hormone replacement among survivors of
childhood cancer. The ideal regimen should aim to benefit the cardiovascular,
skeletal and reproductive health of these young people.
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CHAPTER 7: Pubertal induction and cyclical sex steroid




The onset of puberty in girls is determined by development of the breast buds and an
acceleration in growth velocity. The mean age for onset of puberty is 10.8 years with
a normal range from 8 to 13 years. There is a gradual progression in development of
secondary sexual characteristics, with onset of menses occurring at a mean age of
12.8 years, with a normal range of 8 to 13 years. Some girls are at significant risk of
failure of normal pubertal progress, either as a consequence of gonadal failure (for
example, girls with Turner's syndrome, autoimmune ovarian failure or
galactossaemia, or following treatment for childhood cancer) or lack of central drive
(hypogonadotrophic hypogonadism).
The changes are driven by increasing activity of the hypothalamic pituitary axis, with
gradually increasing levels of oestradiol. For girls with ovarian failure before the
onset of puberty, pubertal induction is required for development of normal secondary
sexual characteristics and for skeletal maturation, to achieve growth acceleration and
optimize bone mineral accretion. The aim of induction is to mimic the natural timing
and rate of progression, although there may be advantages for some girls in delaying
the onset of induction to improve final height. Girls are given gradually increasing
doses of an oestrogen. A prerequisite of the choice of preparation is that it is
available in a small enough dosage to mimic early oestrogen exposure in normal
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puberty. For young women with ovarian failure, who have either progressed through
puberty spontaneously or had puberty induced with low dose oestrogen, cyclical
hormone replacement therapy, with an oestrogen and a progestin, is required. A
progestin enables the endometrial lining to be lost on a cyclical basis, and therefore
the risk of endometrial hyperplasia, and the inconvenience of menstrual spotting are
significantly reduced.
Induction of puberty has been mainly achieved using oral synthetic oestrogen and
progesterone. Although the treatment is effective, it has disadvantages. Oral
oestrogens have variable bioavailability due to intestinal and hepatic first pass
metabolism, which also affects hepatic activity and the clotting system. The natural
form of estrogen in humans is estradiol, but it is relatively ineffective after oral
administration because of extensive degradation in first pass metabolism in the liver.
There is no agreed consensus on the optimum oestrogen and progesterone
preparations for young women with premature ovarian failure. The aim is to achieve
optimal reproductive, skeletal and cardiovascular health, but the evidence is not
available to dictate best practice (Conway., 2001).
7.1.2 Skeletal health
Oestrogen is a potent stimulator of bone mineral accretion through puberty and into
the third decade, when peak bone mass is achieved (Slemenda et al., 1994). An
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adequate peak bone mass reduces the risk of osteoporosis and fractures in later life.
Premenopausal levels of oestradiol in women with normal ovarian function protect
the female skeleton from rapid demineralisation (Howell et al., 1999). However,
bone loss proceeds at an increased rate following the menopause (Krolner et al.,
1982). In Turner syndrome evidence suggests that women do not achieve peak bone
mass and have a higher rate of fractures (Davies et al., 1995). In girls with Turner
syndrome the rate of bone mineral acquisition on the OCP is less than is seen in
healthy girls, with a 25% reduction in bone mineral content (BMC) from that
predicted for age, height, weight and bone size which may be due to suboptimal
oestrogen replacement (Shore et al., 1982). Studies have suggested that prolonged
OCP use in skeletally immature females leads to a lower peak bone mass (Register et
al., 1997). A decrease in BMC and an increased risk of osteoporosis have been
demonstrated in survivors of childhood cancer (Hoorweg-Nijman et al., 1999). This
may be due to both suboptimal oestrogen replacement and the treatment received for
the cancer. Optimising oestrogen replacement may improve bone mineral accretion
and reduce the risk of long term morbidity from osteoporosis in women with ovarian
failure.
7.1.3 Cardiovascular health
Optimal sex steroid replacement may reduce the risk of cardiovascular disease in
young women with premature ovarian failure. The cardiovascular protective effects
of oestrogen are well documented in older women who have had endogenous
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protection for many years before the menopause (Mendlesohn et al., 1999).
However, The Women's Health Initiative has shown that continued exposure to HRT
beyond the normal timing of the menopause increases the risk of cardiovascular
events (Manson et al., 2003)
Direct actions of oestrogen on blood vessels and effects on serum lipid
concentrations reduce the risk of cardiovascular disease in premenopausal women.
The vasculature, like the reproductive tissues, bone, liver and brain, is now
recognised as an important target organ of oestrogen's action. Oestrogen increases
vasodilatation and inhibits the response of blood vessels to injury and the
development of atherosclerosis. The incidence of atherosclerotic disease rises in
postmenopausal women. There is no current information regarding cardiovascular
risk factors in women with premature ovarian failure treated with current hormone
replacement regimens. However women with Turner syndrome have a higher
incidence of hypertension and cardiovascular disease. Radiotherapy and
chemotherapy have a deleterious effect on cardiovascular function, with recognised
risks for decreased cardiac function being radiation exposure and chemotherapy,
particularly anthracycline treatment (Hansen et al., 1989, Stewart et al., 1995). Thus
these women are at increased risk of cardiovascular disease.
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7.1.4 Reproductive health
Current SSR may not achieve optimal reproductive health. Women with Turner
syndrome who have achieved pregnancy with donor oocytes have an increased risk
of miscarriage, still birth and premature delivery (Kaneko et al., 1990). This may
relate to poor endometrial or uterine function (Yaron et al., 1996). Uterine volume in
women with Turner syndrome who have required pubertal induction with exogenous
steroids is reduced and this may effect their reproductive potential (Paterson et al.,
2002). Treatment for childhood cancer may have major effects of uterine function if
the uterus lies in the radiation field (Hawkins et al., 1989; Critchley et al., 1992).
Changes in uterine size and blood flow may be used as an internal control, as
changes in uterine parameters are a biological marker of response to SSR.
Physiological SSR improves parameters of uterine function, which is a valuable
marker of response in a biological target organ (Bath et el., 1999).
We evaluated the current practice within the UK to determine the most commonly
used regimens. The aim of the study was to provide evidence of current practice, so




The prescribing habits of all members of European Society of Paediatric
Endocrinology practicing in the United Kingdom were surveyed. A questionnaire
was sent enquiring as to their choices of hormone replacement for pubertal induction
and subsequent hormone replacement in young women with premature ovarian
failure. There was an option to document first, second and third choice ofHRT. The
respondents were asked the rationale for their first choice ofHRT. The questionnaire




Forty two questionnaires were sent, and the response rate was 71% (n = 30). All
respondents, except one, used oral ethinyloestradiol, available as 2 and 10 microgram
tablets, for pubertal induction. Hormone replacement choice for the post pubertal girl
produced a much more varied response as shown in table 7.1. Two respondents did
not have a preferred hormone replacement regimen.
The only consistent reason given for choice of oral contraceptive was convenience
and patient's acceptability.
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Table 7.1. Choice of hormone replacement for post pubertal
women with premature ovarian failure (n = 28)
Method of hormone replacement
n (%)
Preferred preparation
in each category n (%)
Combined oral contraceptive 18 (64) Loestrin (20 or 30) 12 (67)
Hormone replacement
oral (cyclical progestin)
5 (18) Prempak C 5 (100)
Hormone replacement
transdermal (cyclical progestin)








There was consensus regarding the preparation used to induce puberty. However,
there is evidence that use of a more physiological regimen, with transdermal
oestrogen, increasing slowly over 4-5 years, with the dose tailored to an individuals
levels, may have benefits on uterine growth (Piippo et al., 2004). There was no
negative effect on final height, and benefits of cardiovascular and skeletal health
were not demonstrated in these small studies.
There was no consensus in prescribing cyclical HRT for young women with ovarian
failure who face many decades of oestrogen replacement therapy. The reason given
for the choice of oral contraceptive pill was convenience of preparation, ease of use
and social acceptability. Although this is a justifiable rational for prescribing, it may
not be the optimal preparation for skeletal and cardiovascular health.
Further research is required to determine the optimum sex steroid replacement
regimen for women with premature ovarian failure. The aim of treatment should be
to achieve optimum psychological and physical well being. The long term follow up
ofwomen with premature ovarian failure needs to be within a multidisciplinary team
who can also address the varying health aspects of both the underlying cause for the
premature ovarian failure, and the need to optimise future health.
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CHAPTER 8: Spontaneous conception in a teenager who
had ovarian cortical tissue cryopreserved before
chemotherapy and radiotherapy for a Ewing's sarcoma of
the pelvis
8.1 Case report
A 14.9 year old girl who presented with a 2 year history of left groin pain.
Radiological investigation demonstrated a bony mass, 1 lOmls in volume, arising
from left superior pubic ramus that, on biopsy, was confirmed to be a Ewing's
sarcoma. There was thought to be a high risk of ovarian failure resulting from the
proposed radiotherapy to the tumour site. After detailed discussion informed consent
was obtained from the girl and her parents for laparoscopic collection of ovarian
cortical strips. These were stored in Leibovitz medium at -176 °C. Treatment was
commenced in accordance with the EICESS 1992 protocol; 14 courses of
chemotherapy, with a total dose of ifosfamide of 86.4g/m2, and 55 Gray to her left
pelvis. The radiation field was as shown in figure 8.1. The treatment was completed
aged 15.8 years.
Ovarian function was monitored following diagnosis. After completion of
radiotherapy aged 15.3 years, there were symptoms and biochemical evidence of
ovarian failure; hot flushes, elevated gonadotrophins and undetectable inhibin B (see
figure 8.2). Loestrin 20 was commenced and continued until completion of
chemotherapy. There was intermittent vaginal spotting and HRT was discontinued
for three months on completion of treatment. Re-evaluation of her biochemical data
confirmed ovarian failure with significant elevation of gonadotrophins and
undetectable inhibin B with absent menses. HRT was restarted but persistent vaginal
bleeding continued. A variety of preparations were tried, as detailed in figure 8.2.
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Figure 8.1 MRI scan of pelvis for radiotherapy planning - numbers
indicate percentage of total dose received by each area
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Aged 16.7 years, while on HRT, a transabdominal ultrasound scan of her pelvis
demonstrated a uterine volume of length of 5.9 cm (AP 2.6 cm, transverse 3 cm) with
an endometrial echo. The left ovarian volume was 2.2 mis and the right 4.2 mis. No
evidence of follicular activity was seen and no vascular signals were obtained from
either ovary. Hormone replacement therapy was discontinued for 3 weeks after
which gonadotrophin levels indicated ovarian failure (see figure 8.2). Continuous
transdermal oestradiol with oral progesterone every 2 weeks was then recommenced.
Further evaluation of the persistent vaginal bleeding, on the above regimen, at the
age of 18.5 years included an examination under anaesthesia, a cervical smear, a
biopsy of vaginal wall, a hysteroscopy and a pipelle biopsy. Examination revealed an
atrophic lower vaginal tract. Biopsy of the vaginal wall showed chronic
inflammation and ulceration thought to be a radiation effect. The uterine cavity
appeared normal and the pipelle biopsy showed normal early secretory phase
endometrium. Radiation damage to the lower vaginal tract was thought to be the
cause for the bleeding and topical oestrogen was prescribed in addition to
transdermal oestradiol. The intermittent spotting improved.
The question of fertility was raised at the age of 19.7 years following the onset of
sexual activity and decision to get engaged. There was no dyspareunia or vaginal
bleeding. Consideration was given to reimplantation of cortical slices and
consultation was organised with the Gynaecology Department. After discussion the
decision for reimplantation was deferred for personal reasons and hormone
replacement therapy continued.
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An ultrasound scan was organised aged 20.2 years following a history of abdominal
pain and vaginal bleeding. The USS demonstrated an early intrauterine pregnancy.
The bleeding resolved and the pregnancy progressed. Maternal and fetal health were
monitored throughout the pregnancy. Cardiac assessment was necessary as the
chemotherapy protocol included cardiotoxic agents (anthracyclines). Pelvic
assessment was required to consider optimum mode of delivery in view of previous
pelvic mass and radiotherapy. Regular fetal growth assessments were performed in
view of concern of potential effect of radiotherapy on uterine function. Fetal growth
progressed normally.
The history of radiotherapy and pelvic mass indicated that vaginal delivery might be
difficult. There was the risk that operative complications may have been avoided by
normal delivery. If normal delivery had not been possible then emergency caesarian
section could have been a technically difficult procedure. After discussion between
colleagues and with the family a decision was made to proceed to elective caesarian
section. At 38 weeks gestation a healthy baby boy was delivered weighing 2940g (3rd
- 10th centile). Intra operative examination of the pelvic structures revealed normal
ovaries and pelvic bones with no evidence of radiation damage.
After delivery there was spontaneous return of menses. Menses have remained
regular, occurring approximately once every 28 days without any hormone
replacement therapy. Early follicular gonadotrophin levels have been within or just
above the normal reference range (see figure 8.2). A pelvic ultra sound scan 15
months after delivery showed uterine length to be 7.3 cm, (AP 3.7 cm, transverse
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5.3cm). The uterine artery blood flow was normal. The left ovary was not seen. The
right ovary was unremarkable and measured 1.9 x 1.8 x 1.5 cm (volume 2.3 mis).
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8.2 Discussion
The treatment for pelvic Ewing' sarcoma is thought to carry a significant risk of
ovarian failure. In this case, there was clinical and biochemical evidence of ovarian
failure on completion of treatment with elevated FSH levels and undetectable inhibin
B. The left ovary received the full dose of radiation (55 Gy), but it is harder to
estimate the dose received by the right ovary. The position of the ovary varies,
dependent on bladder and bowel contents. The best estimate is that the right ovary
received less than 30% of the total dose (< 16.5 Gy); therefore there could have been
a significant scatter dose to the right ovary and therefore depletion of primordial
follicles (Wallace et al., 2003). The effect of the chemotherapy is hard to determine.
There are no good data regarding gonadal toxic doses of ifosfamide.
Cyclophosphamide, an analogue of ifosfamide, is associated with gonadal toxicity.
Doses is excess of 200mg/m2 are associated with ovarian failure (Sanders et al.,
1991). The ovarian failure is likely to be a consequence of both radiotherapy and
chemotherapy. After delivery there was spontaneous return of menses, with
gonadotrophins within the normal range. However at 15 months post delivery there
was evidence of incipient ovarian failure with elevated FSH and small ovarian
volume consistent with a decreased primordial follicle pool, as a consequence of the
previous therapy.
The risk of ovarian failure can be estimated prior to gonadal toxic therapy and
information regarding the risk should be discussed with the patient. Exact prediction
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is not possible as this case demonstrates, but fertility preservation should be
discussed with those deemed at high risk of ovarian failure. A number of strategies to
protect the ovaries and preserve fertility during cancer therapy have been attempted
with limited success. Limitation of radiation dose to the ovary is sometimes practiced
in adult women but in children is technically difficult. Ovarian translocation will
reduce the radiotherapy exposure to the gonad (Leporrier et al., 1987).
Gonadotrophin suppression has been shown to offer some protection from
chemotherapy induced ovarian damage (Blumenfeld et al., 1996) but no benefit has
been shown in radiation induced ovarian failure. For prepubertal girls, and the
majority of young women, preservation of fertility remains experimental and
harvesting and storage of gonadal tissue before commencing cancer therapy is the
most promising option (Grundy et al., 2001a; Grundy et al., 2001b; Multidisciplinary
Working Group, 2003; Poirot et al., 2002). There are reports in the literature of
return of ovarian function following reimplantation of cortical strips in
ovariectomised sheep and subsequent conception (Gosden et al., 1994).
Reimplantation and return of ovarian activity has been reported in a woman who had
received gonadal toxic therapy prior to ovarian cortical collection, but no live births
reported (Radford et al., 2001).
Ovarian function following gonadal toxic therapy can be evaluated clinically,
biochemically and radiologically. Ovarian failure presents with absent menses and
symptoms of oestrogen withdrawal, elevated gonadotrophins and small ovaries.
Incipient ovarian failure may be detected by early follicular biochemical assessments
of gonadotrophins and inhibin B (Creus et al., 2000). Recently anti-Mullerian
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hormone has been shown to be a potential marker of ovarian reserve (de Vet et al.,
2002; Bath et al., 2003). Radiological assessment of ovarian volume may also be a
potential predictor of reserve, with ovarian volume correlating with number of
remaining follicles (Syrop et al., 1999; Larsen et al., 2003).
Return of ovarian function and conception years after gonadal toxic chemotherapy
and biochemical evidence of ovarian failure has been previously reported (Nasir et
al., 1997). There are few reports of return of ovarian function after radiation induced
ovarian failure (Chao et al., 1998). Destruction of primordial follicles results in
decreased ovarian reserve. Early ovarian failure following therapy has been related to
lack of maturing antral follicles due to lack of follicle recruitment and atresia of
antral follicles during chemotherapy. Early data from autopsy specimens of children
with leukaemia directly demonstrated a reduction in antral follicle number following
chemotherapy (Himmelstein-Braw et al., 1978). Return of ovarian activity several
months after completion of therapy and after documented biochemical ovarian
failure is well recognised. The reason for return of ovarian activity years after
documented evidence of ovarian failure is not known. Women with premature
ovarian failure after gonadal toxic therapy should be aware of the small but possible
chance of return of function and therefore conception.
Chemotherapy has not been shown to have any deleterious effect on uterine function
in contrast to pelvic irradiation (Critchley et al., 1992). Radiotherapy to the uterus
increases the risk of miscarriage with a high risk of mid trimester loss in women
treated prepubertally with pelvic irradiation (20-30 Gray)(Wallace et al., 1989). The
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risk relates to age at irradiation (Bath et al., 1999). Pre pubertal radiation exposure
increases the risk of mid trimester losses (Sanders et al., 1996).
Collection of ovarian tissue as a potential method of preserving reproductive
potential is available in certain centres. In this case, consideration had been given to
reimplantation of cortical strips as fertility was not thought possible, given the
clinical and biochemical evidence of ovarian failure. The spontaneous conception
could have then been attributed to successful re-engraftment and function of the
stored cortical tissue. Currently there are no reports of conception post
reimplantation of ovarian cortical strips in humans. Autologous ovarian
transplantation carries future risks of recurrence of the original cancer and we believe
that in vitro maturation of ovarian follicles that have survived freeze/thawing is
likely to be available in the future with less risk. The cryopreservation of ovarian
cortical tissue is an experimental method of preserving primordial follicles and, with
the development of in vitro maturation, may have the potential to preserve fertility in






Fertility is a major concern for women who have survived cancer during childhood,
and is of increasing importance as currently 70% of children treated for malignant
disease will become long term survivors. The work in this thesis has further informed
the issues related to hypothalamic ovarian function after cranial irradiation,
investigation of ovarian reserve in women potentially at risk of premature
menopause, the risk of ovarian failure post TBI, the uterine characteristics post TBI,
and the current practice regarding HRT in those women with ovarian failure.
Women with ovarian failure need an evidence base to aid choice in hormone
replacement. For those girls who require potentially sterilising therapy, options for
fertility preservation should now be considered. For those women who have had non-
sterilising therapy, they remain at risk of a premature menopause and ongoing review
of this population is imperative to document evolving late effects.
9.1.2 Ovarian function after low dose cranial irradiation.
The data demonstrate that low dose cranial irradiation has an adverse effect on the
hypothalamic - pituitary - ovarian axis that may be progressive over time. The
166
women had regular menses and normal ovulatory cycles, evidenced by an LH surge
and rise in P3G. Early follicular gonadotrophin and inhibin B levels were normal.
Ultrasonography demonstrated normal ovaries. These indices are reassuring
regarding current ovarian reserve.
However, subtle effects on hypothalamic - ovarian function were demonstrated. LH
secretion was decreased throughout the cycle, especially during the LH surge. Short
luteal phases were demonstrated; the LH surge was most deficient in those cycles
with short luteal phases. Increasing time since treatment increased the chance of a
poor LH surge. The function of the corpus luteum is dependent on LH secretion,
especially the magnitude and duration of the LH surge. Oestrone secretion was lower
during the follicular phase and the luteal phase. Oestrone production is under the
influence of both LH and FSH, and decreased LH secretion was demonstrated
throughout the cycle.
Apparently minor disturbances in LH secretion may have an effect on reproductive
potential: conception in normal women is more likely in cycles with greater LH
surges and higher luteal phase progesterone and oestradiol. Short luteal phases are
associated with reduced fertility and early miscarriage.
Detailed analysis of reproductive endocrine function at long term follow up of
treatment for childhood ALL has not been previously reported. Other reports include
a variety of primary diagnoses and therefore varying treatment strategies. Therefore
direct comparison is not possible.
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Survival after treatment for childhood ALL is greater than 70%, and current
protocols aim to increase the survival rate while reducing treatment induced late
effects. Low dose cranial irradiation is no longer standard therapy, following the
recognition of significant late effects and the confirmation that alternative CNS
directed therapies are as effective. There remain a significant number of survivors of
leukaemia who have received treatment with chemotherapy and cranial irradiation.
The data regarding long term fertility is encouraging. Continued assessment of these
women will provide further information regarding fertility rates, and detailed
evaluation will provide information on both hypothalamic and ovarian effects over
time.
9.1.3 Depletion of ovarian reserve after treatment for cancer in
childhood.
The agents used to treat the childhood malignancies will potentially destroy a
significant number of the finite number of follicles. The number cannot accurately be
predicted, even if the chemotherapy doses and radiation schedules are known. It
would therefore be of great value to be able to assess ovarian reserve in women with
regular menses or on the OCP.
The data demonstrated that in women with regular cycles, serum FSH was
significantly higher and serum AMH significantly lower in the cancer survivors
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compared with controls. Other markers of ovarian function, inhibin A, B and
oestradiol were not significantly different from controls. Ovarian volume, but not
antral follicle count, were also reduced in survivors compared to controls. These data
are consistent with cancer survivors having a near normal compliment of small antral
follicles. AMH is produced by the granulosa cells of small growing follicles and may
therefore reflect more accurately ovarian reserve. AFC and inhibin B reflect the
number of FSH sensitive small antral follicles. The higher FSH levels in the
survivors may drive increased follicle recruitment, and hence normal antral follicle
count and inhibin B levels.
During COCP administration inhibin B was suppressed to undetectable levels in both
cancer survivors and controls. In response to FSH stimulation, all controls showed a
response, whereas in the cancer survivors, only 6 of 10 showed a response. The AFC
was significantly lower in the cancer survivors compared to controls. The results
suggest that cancer survivors show a degree of depletion of ovarian reserve and
under conditions of hypogonadism, this is reflected in a reduction in the number of
FSH sensitive antral follicles.
The underlying diagnoses of the cancer survivors were varied and therefore no
comment can be made on individual treatment regimens and the related risk of
depletion of ovarian reserve. However, all these women had received non-sterilising
chemotherapy in childhood, and these results indicate that there is an effect on
ovarian reserve. Detailed follow up of these women is therefore essential to clinically
confirm these findings.
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9.1.4 Ovarian and Uterine characteristics after TBI
Following TBI in childhood and adolescence we have confirmed that the majority of
women have permanent ovarian failure. The risk is greater for those treated post
pubertally, but even those with preserved ovarian function have evidence of reduced
ovarian reserve.
At baseline, all women with ovarian failure had a small uterus, with poor blood flow
and absent endometrium. Following physiological sex steroid replacement for 3
months all measures of uterine function improved such that there was no significant
difference in uterine blood flow and endometrial thickness from the comparison
group. Uterine volume, although increased with pSSR, remained significantly less
than the comparison group. There was a correlation between age at irradiation and
uterine volume, indicating that those treated prepubertally had smaller volumes.
Optimising hormone replacement may therefore improve uterine function,
particularly uterine blood flow and endometrial thickness. Flowever, caution should
remain regarding uterine distensibility, especially in those treated prepubertally, as
uterine volume remained significantly smaller and there are several reports in the
literature of 2nd trimester miscarriage in this group of survivors.
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9.1.5 Choice of HRT in females with premature ovarian failure
There is no consensus regarding the choice of hormone replacement therapy in
females with premature ovarian failure. The evidence is not available to dictate best




The treatment of childhood cancer carries a risk of depletion of ovarian follicles. We
have demonstrated a high risk with TBI, but a low risk with standard treatment for
ALL. Treatment regimens aim to cure but the identification of therapies that confer a
significant risk of long term damage has driven changes in chemotherapy regimens,
for example as in the treatment of Hodgkin's disease. However, for certain
malignancies, the risk of ovarian damage has been accepted given the increased
chance of a cure. Identification of which therapies are associated with a high risk of
ovarian failure has therefore been a driving force in research into preservation of
ovarian function for the prepubertal girl.
Studies have evaluated suppression of the hypothalamic pituitary ovarian axis with
gonadotrophin releasing hormone analogues in post pubertal women. There has been
no evidence that this achieves significant gonadal protection and does not seems to
halt the decline in numbers of primordial follicles.
The options for preserving fertility for the prepubertal girl are limited. There has
been much interest in the cryopreservation of primordial follicles for young girls as a
method of preserving reproductive potential. In the 1950s autografts of mouse
ovarian tissue were shown to survive after freezing and thawing (Parkes., 1957).
Normal offspring were obtained from mice with orthotopic ovarian grafts that had
been frozen and stored, although the reproductive life of the females was short
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(Parrot., 1960). In the 1990s this method of restoring fertility to oophorectomised
animals was studied in sheep (Gosden et al., 1994). Ovarian cortical strips were
frozen and reimplanted after oophorectomy. Return of oestrous cycles was
demonstrated although gonadotrophin levels remained higher than the precastrate
range.
The collection and storage of ovarian cortical tissue for girls and young women
before gonadal toxic therapies has been a possibility since the mid 1990s, and has
been available in some centres. Tissue is collected laparoscopically under general
anaesthesia. The tissue is then stored in cryoprotectant and frozen at -196°C in liquid
nitrogen. The Royal College of Obstetricians and Gynaecologists has produced a
report from a working party on the storage of ovarian and prepubertal testicular
tissue (RCOG Storage of ovarian and prepubertal Testicular tissue., 2000) . This
provides standards for best practice in cryopreservation of gonadal tissue, including
the criteria for providing a service, patient identification and selection, standard
operating procedures and aspects of storage.
The future use of the tissue will be dictated by available options. Currently the only
method by which follicle maturation is possible is reimplantation of the tissue, onto
structures within the abdominal/pelvic cavity. The functional lifespan of the strips is
related to the number of follicles that survive the re-engrafitment process, estimated
to be approximately 70% (Oktay et al., 1997). One of the advantages of ovarian
cortical tissue is that there are many primordial follicles potentially able to survive
the freeze thaw process. The younger the child, the greater the number of primordial
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follicles present in the harvested tissue. There are concerns that the reimplanted
tissue may transmit the original disease, as the gonads are recognised sanctuary sites
for malignant cells, particularly for haematological malignancy (Shaw et al., 1996;
Oktay et al., 2000).
There is debate as to who should be offered the collection of ovarian cortical tissue.
There is therefore an urgent need to provide consensus as to the future for fertility
preservation in children (Wallace et al., 2001). It is available in some centres and
there is increasing public awareness of its potential to preserve fertility. The criteria
that have been agreed locally are shown in table 9.1.
Although it has been demonstrated that human primordial follicles survive
cryopreservation and return of ovarian hormonal activity has been achieved with
reimplantation, it remains an experimental procedure. However, one pregnancy has
now been reported and the authors argue that the follicle matured from the
transplanted tissue, not the remaining ovarian tissue (Donnez et al., 2004).
For those women with ovarian failure there is the option to consider donor oocytes.
However, given our data regarding uterine function post radiation, clinicians should
be cautious about the chance of a successful outcome in women in whom the uterus
has been exposed to radiotherapy prepubertally.
For those women not at high risk of ovarian failure, we have shown that ovarian
reserve can be evaluated with biochemical markers, and ultrasound imaging. A
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recent paper (Wallace at al., 2004) evaluated the use of ovarian volume in prediction
of ovarian reserve. They demonstrated a highly significant correlation between
primordial follicle population and ovarian reserve, and suggested that this would
revolutionise the management of women seeking advice regarding reproductive
status. However, further longitudinal studies need to be done to monitor reproductive
function in women who have had treatment that may deplete ovarian reserve. This
would further inform clinicians about the long term risks of treatment and enable
clinicians to inform patients about the potential risks.
For those women that have ovarian failure, there is a need to optimise hormone
replacement. Evidence is required to dictate best practice. Studies in women with
ovarian failure evaluating the benefits of a physiological regimen versus standard
replacement therapy are ongoing. The choice of the standard HRT within one arm of
the study was dictated by the questionnaire regarding current UK choice of HRT in
women with premature ovarian failure. However, the final choice ofHRT should be
the patients own, once the various options, and associated risks and benefits have
been discussed. Hormone replacement therapy came under question after the report
for the Women's Health Initiative (Manson et al., 2003). Although this report was
not relevant to young women who have premature ovarian failure, it does highlight
the need for an evidence base. Long term studies are therefore required and, given
that the numbers ofwomen are small, multi-centre collaboration would be essential.
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9.3 Future research plans originating from this thesis
The initial drive to research into the late effects of the treatment of childhood cancer
came from the recognition of significant morbidity and mortality from the treatment
schedules. The current schedules aim to maximise the chance of cure, while
recognising the need to balance the risk of late effects. It is therefore essential to
continue to monitor survivors of childhood cancer to determine the effect of current
protocols on late effects, including fertility. There is very little population based data
regarding long term fertility in survivors of childhood cancer. The UKCCSG has a
database of all patients and therefore would facilitate tracing of all survivors. We aim
to study the fertility in female survivors as a nationwide study, with an initial pilot
study in Scotland. We would take forward the work on assessment of ovarian
reserve, using ultrasound imaging to determine ovarian volume and antral follicle
count, and early follicular biochemical assessment of FSH, LH, inhibin B and AMH.
An initial cross sectional study could be the preliminary work necessary for
longitudinal studies assessing ovarian function in cancer survivors.
The current data do not allow for accurate prediction of ovarian reserve for an
individual. There is significant intercycle variability in all these markers. Serial
measurements improve the reliability of these assessments. Longitudinal data
detailing progression in these markers over time, in relation to the timing of the
menopause, will determine whether they have a place in prediction for an individual.
However, the recognition that conceptions occur in women who have had
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documented ovarian failure highlights the fact that even with accurate biochemical
and ultrasound assessment it may never be possible to predict with certainty for an
individual.
The second line of research we are pursuing is the assessment of optimum hormone
replacement in women with premature ovarian failure. Current HRT choice is not
evidenced based for the young woman with premature ovarian failure. Although the
cohort of survivors with ovarian failure from childhood cancer is small, there are
other groups of women who could benefit from optimising HRT. We are currently
studying women with Turners syndrome, women with ovarian failure after childhood
cancer and women with idiopathic ovarian failure in a crossover study comparing
physiological sex steroid replacement regimen against a standard COCP, to
determine whether there are benefits as assessed by markers of cardiovascular,
skeletal and reproductive health.
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Table 9.1. Edinburgh criteria for selection of patients for
cryopreservation of ovarian cortical tissue
Age <30 years
No previous chemotherapy/radiotherapy
(if aged <15 years consider if previous 'low-risk' chemotherapy)
A realistic chance of long-term survival
A high risk of treatment-induced immediate ovarian failure (estimated at
>50%)
Informed consent (from patient or in the case of an incompetent child
from the parents)




Ahmed Ebbiary N A, Lenton E A, Cooke ID (1994) Hypothalamic-pituitary ageing:
progressive increase in FSH and LH concentrations throughout the reproductive life
in regularly menstruating women. Clinical Endocrinology 41, 199-206.
Baarends W M, Uilenbroek J T, Kramer P, Hoogerbrugge J W, van Leeuwen E C,
Themmen A P et al (1995) Anti-mullerian hormone and anti-mullerian hormone type
II receptor messenger ribonucleic acid expression in rat ovaries during post natal
development, the estrous cycle, and gonadotrophin induced follicle growth.
Endocrinology 136, 4951-4962.
Baird D T, Weinberg C R, Zhou H et al (1999) Preimplantation urinary hormone
profiles and the probability of conception in healthy women.. Fertility and Sterility
71, 40-49.
Barreca A, Artini P G, Del Monte P et al (1993) In vivo and in vitro effect of growth
hormone on Estradiol secretion by human granulosa cells. Journal of Clinical
Endocrinology andMetabolism 77, 61-67.
179
Bath L E, Anderson R A, Critchley HOD, Kelnar C J H, Wallace W H B (2001)
Hypothalamic-pituitary-ovarian dysfunction after prepubertal chemotherapy and
cranial irradiation for acute leukaemia. Human Reproduction 16, 1838-1844.
Bath L E, Critchley HOD, Chambers S E, Anderson R A, Kelnar C J H, Wallace W
H B (1999) Ovarian and uterine characteristics after total body irradiation in
childhood and adolescence: response to sex steroid replacement. British Journal of
Obstetrics and Gynaecology 106, 1265-1272.
Bath L E, Wallace W H B, Shaw M P, Fitzpatrick C, Anderson R A (2003)
Depletion of the ovarian reserve in young women following treatment for cancer in
childhood: detection by anti-Mullerian hormone, inhibin B and ovarian ultrasound.
Human Reprodroduction 18, 2368-2374.
Birkebaek N H, Kisker S, Clausen N et al (1998) Growth and endocrinological
disorders up to 21 years after treatment for acute lymphoblastic leukaemia in
childhood. Medical andPaediatric Oncology 30, 351-356.
Block E (1952) Quantitative morphological investigations of the follicular system in
women. Variations at different ages. Acta Anat 14, 108-123.
Blum W F (1996) Insulin like growth factors and their binding proteins. In
Diagnostics ofEndocrine function in Children and Adolescents, pp. 100-218 [Ranke
MB, editor], Heidelberg: Barth JA.
180
Blumenfeld Z, Avivi I, Linn S et al (1996) Prevention of irreversible chemotherapy-
induced ovarian damage in young women with lymphoma by a gonadotrophin-
releasing hormone agonist in parallel to chemotherapy. Human Reproduction 11,
1620-1626.
Bramswig J H, Heiermann E, Heimes U et al (1989) Ovarian function in 63 girls
treated for,Hodgkins disease according to the West German DAL-HD-78 and DAL-
HD-82 therapy study. Medical and Paediatric Oncology 17, 344.
Brennan B M, Rahim A, Mackie E M et al (1998) Growth hormone status in adults
treated for acute lymphoblastic leukaemia in childhood. Clinical Endocrinology 48,
777-783.
Burger H G, Cahir N, Robertson D M et al (1998) Serum inhibins A and B fall
differentially as FSH rises in perimenopausal women. Clinical Endocrinology 48,
809-813.
Burnett A K, Eden O B (1997) The treatment of acute leukaemia. Lancet 349, 270-
275.
Byrne J (1999) Infertility and premature menopause in childhood cancer survivors.
Medical andPediatric Oncology 33, 24-28.
181
Byrne J, Fears T R, Gail M H, Pee D, Connelly R R, Austin D F, Holmes G F,
Holmes F F, Latourette H B, Meigs J W et al (1992) Early menopause in long term
survivors of cancer during adolescence. American Journal of Obstetrics and
Gynaecology 166, 788-793.
Chao H T, Wang P H, Yuan C C, Lee W L (1998) Successful pregnancy outcome in
a women with acute myeloid leukaemia treated with high dose whole body
irradiation. Journal ofReproductive Medicine 43, 703-706.
Chessells J M (1998) Relapsed lymphoblastic leukaemia in children: a continuing
challenge. British Journal ofHaematology 102, 423-438.
Chessells J M, Richards S M, C BC et al (1995) Gender and treatment outcome in
childhood lymphoblastic leukaemia: report from the MRC UKALL trials. British
Journal ofHaematology 89, 364-372.
Clough K B, Goffinet F, Labib A et al (1996) Laparascopic unilateral ovarian
transposition prior to irradiation. Cancer 77, 2638-2645.
Conway G (2001) Oestrogen replacement in young women with turner's syndrome.
Clinical Endocrinology, 54, 157-158.
Cook C L, Siow Y, Taylor S, Fallat M E (2000) Serum mullerian inhibiting
substance levels during normal menstrual cycles. Fertility andSterility 73, 859-861.
182
Creus M, Penarrubia J, Fabregues F, Vidal E, Carmona F, Casamitjana R, Vanrell J
A, Balasch J (2000) Day 3 serum inhibin B and FSFi and age as predictors of assisted
reproduction treatment outcome. Human Reproduction 15, 2341-2346.
Critchley HOD, Bailey D A, Au C L, Affandi B, Rogers PAW (1993)
Immunohistochemical sex steroid receptor distribution in endometrium from long
term subdermal levonorgestrel users and during the normal menstrual cycle. Human
Reproduction 8, 1632-1639.
Critchley HOD, Buckley C H, Anderson D C (1990) Experience with a
physiological steroid replacement regimen for the establishment of a receptive
endometrium in women with premature ovarian failure. British Journal ofObstetrics
and Gynaecology 97, 804-810.
Critchley HOD, Wallace W H B, Shalet S M, Mamtora H, Higginson J, Anderson
D C (1992) Abdominal irradiation in childhood; the potential for pregnancy. British
Journal ofObstetrics and Gynaecology 99, 392-394.
Critchley HOD, Wang H, Kelly R W, Gebbie A E, Glasier A F (1998) Progestin
receptor isoforms and prostaglandin dehydrogenase in the endometrium of women
using a levonorgestrel-releasing intrauterine system. Human Reproduction 13, 1210-
1217.
183
Critchley HOD, Warner P, Lee A J, Brechin S, Guise J, Graham B (2004)
Evaluation of abnormal uterine bleeding: comparison of three outpatient procedures
within cohorts defined by age and menopausal status. Health Technol Assess 8, 1-
154.
Crofton P M, Evans A E, Groome N P, Taylor M R, Holland C V, Kelnar C J H
(2002) Dimeric inhibins in girls from birth to adulthood: relationship with age,
pubertal stage, FSH and oestradiol. Clin Endocrinol 56, 223-230.
Crowne E C, Moore C, Wallace W H B et al (1992) A novel variant of growth
hormone insufficiency following low dose cranial irradiation. Clin Endocrinol 36,
59-68.
Cruz J R, Gindoff P R (1999) Age and reproduction. ReprodMedRevs 7, 61-69.
Davies M C, Guleki B & Jacobs H S (1995) Osteoporosis in Turner's syndrome and
other forms of primary amenorrhoea. Clinical Endocrinology 43, 741-746.
Dawood M Y (1994) Corpus luteal insufficiency. Curr Opin Obstet Gynecol 6, 121-
7.
De SouzaM J, Miller B E, Loucks A B, Luciano A A, Pescatello L S, Campbell C G,
Lasley B L (1998) High frequency of luteal phase deficiency and anovulation in
recreational women runners: blunted elevation in follicle-stimulating hormone
observed during luteal-follicular transition. JClin Edocrinol Metab 83, 4220-4232
184
De Souza M J, Van Heest J, Demers L M, Lasley B L (2003) Luteal phase deficiency
in recreational runners: evidence for a hypometabolic state. J Clin Endocrinol Metab
88, 337-346
de Vet A, Laven J S, de Jong F H, Themmen A P, Fauser B C (2002) Antimullerian
hormone serum levels: a putative marker for ovarian aging. Fertility and Sterility 77,
357-362.
Donnez J, Dolmans M aM, Demylle D, Jadoul P, Pirard C, Squifflet J, Martinez-
Madrid B, van Langendonckt A. (2004) Livebirth after orthotopic transplantation of
cryopreserved ovarian tissue. Lancet. 364, 1405-1410.
Dumesic D A, Damario M A, Session D R, Famuyide A, Lesnick T G, Thornhill A
R, McNeilly A S (2001) Ovarian morphology and serum hormone markers as
predictors of ovarian follicle recruitment by gonadotrophins for in vitro fertilisation.
Journal ofClinical Endocrinology andMetabolism 86, 2538-2543.
Durlinger A L, Kramer P, Karels B, de Jong F H, Uilenbroek J T, Grootegoed J A, et
al (1999) Control of primordial follicle recruitment by anti-mullerian hormone in the
mouse ovary. Endocrinology 140, 5789-5796.
Eldar-Geva T, Robertson D M, Cahir N et al (2000) Relationship between serum
inhibin A and B and ovarian follicle development after a daily fixed dose
185
administration of recombinant follicle-stimulating hormone. Journal of Clinical
Endocrinology andMetabolism 85, 607-613.
Faddy M J, Gosden R G, Gougeon A, Richardson S J, Nelson J F (1992) Accelerated
disappearance of ovarian follicles in mid-life; implications for forecasting
menopause. Human Reproduction 7, 1342-1346.
Fanchin R, Schonauer L M, Righini C, Frydman N, Frydman R, Taieb J (2003a)
Serum anti-Mtillerian hormone dynamics during controlled ovarian hyperstimulation.
Human Reproduction 18, 328-332.
Fanchin R, Schonauer L M, Righini C, Guibourdenche J, Frydman R, Taieb J
(2003b) Serum anti-Miillerian hormone is more strongly related to ovarian follicular
status than serum inhibin B, estradiol, FSH and LH on day 3. Human Reproduction
18, 323-327.
Gleeson H K and Shalet S M (2004) The impact of cancer therapy on the endocrine
system in survivors of childhood brain tumours. Endocrine-Related Cancer 11, 589-
602.
Gosden R G, Baird D T, Wade J C, Webb R (1994) Restoration of fertility to
oophorectomized sheep by ovarian autografts stored at -196oC. Human
Reproduction 9, 597-603.
186
Gougeon A, Echochard R, Thalabard J C (1994) Age-related changes of the
population of human ovarian follicles: increase in the disappearance rate of non-
growing and early-growing follicles in aging women. Biol Reprod 50, 653-663.
Green D M, Hall B, Zevon A (1989) Pregnancy outcome after treatment for acute
lymphoblastic leukaemia during childhood or adolescence. Cancer 64, 235-244.
Groome N P, Illingworth P J, O'Brien M et al (1994) Detection of dimeric inhibin
throughout the human menstrual cycle by a 2-site enzyme immunoassay. Clinical
Endocrinology 6, 717-723.
Groome N P, Illingworth P J, O'Brien M, Pai R, Rodger F E, Mather J P, McNeilly A
S (1996) Measurement of dimeric inhibin B throughout the menstrual cycle. Journal
ofClinical Endocrinology andMetabolism 81, 1401-1405.
Grundy R, Gosden R G, Hewitt M, Larcher V, Leiper A, Spoudeas H A, Walker D,
Wallace W H B (2001a) Fertility preservation for children treated for cancer (1):
scientific advances and research dilemmas. Archives ofDisease in Childhood 84,
355-359.
Grundy R, Larcher V, Gosden R G et al (2001b) Fertility preservation for children
treated for cancer (2): ethics of consent for gamete storage and experimantation.
Archives ofDisease in Childhood 84, 360-362.
187
Hall J E, Welt C K, Cramer D W (1999) Inhibin A and inhibin B reflect ovarian
function in assisted reproduction but are less useful at predicting outcome. Human
Reproduction 14, 409-415.
Hann I, Vora A, Richards S et al (2000) Benefit of intensified treatment for all
children with acute lymphoblastic leukaemia: results from MRC UKALL XI and
MRC ALL97 randomised trials. UK Medical Research Council's Working Party on
Childhood Leukaemia. Leukemia 14, 356-363.
Hansen S W, Olsen N (1989) Raynauds Phenomenon in patients treated with
cisplatin, vinblastine, and bleomycin for germ cell cancer: measurement of
vasoconstrictor response to cold. Journal ofClinical Oncology 7, 940-942.
Hawkins M M, Smith R A (1989) Pregnancy outcomes in childhood cancer
survivors; probable effects of abdominal irradiation. International Journal ofCancer
43, 399-402.
Hawkins M M, Stevens M C G (1996) The long term survivors. British Medical
Bulletin 52, 898-923.
Herter L D, Golendziner E, Flores J A, Becker E Jr, Spritzer P M (2002) Ovarian and
uterine sonography in healthy girls between 1 and 13 years old: correlation of
findings with age and pubertal status. Am JRoentgenol 178, 1531-1536.
188
Himelstein-Braw R, Peters H, FaberM (1978) Morphological study of the ovaries of
leukaemic children.. British Journal ofCancer 38, 82-87.
Holm K, Mosfeld T, Larsen E et al (1995) Pubertal maturation of the internal
genitalia: an ultrasound evaluation of 166 healthy girls. Ultrasound Obstet Gynecol
6J,155-181.
Holm K, Nysom K, Brocks V et al (1999) Ultrasound B-mode changes in the uterus
and ovaries and Doppler changes in the uterus after total body irradiation and
allogenic bone marrow transplantation in childhood. Bone Marrow Transplantation
23, 259 - 263.
Hoorweg-Nijman J J G, Kardos G, Roos J C, van Dijk H J, Netelenbos C, Popp-
Snijders C, de Ridder C M, Delemarre-van de Waal H A (1999) Bone mineral
density and markers of bone turnover in young adult survivors of childhood
lymphoblastic leukaemia. Clinical Endocrinology 50, 237-244.
Howell S J, Shalet S M (1999) Aetiology-specific effect of premature ovarian failure
on bone mass - is residual ovarian function important? Clinical Endocrinology 51,
531-534.
Hutchison J S, Zeleznik A J (1984) The rhesus monkey corpus luteum is dependent
on pituitary gonadotropin secretion throughout the luteal phase of the menstrual
cycle. Endocrinology 115, 1780-1786.
189
Kaneko N, Shinnosuke K, Hiroi M (1990) Turner's syndrome - review of literature
with reference to a normal successful pregnancy outcome. Gynaecology and
Obstetric Investigation 29, 81-87.
Klein N, Illingworth P, Groome N, McNeilly A, Battaglia D, Soules M (1996)
Decreased inhibin B secretion is associated with the monotropic FSH rise in older
ovulatory women: A study of serum and follicular fluid levels of dimeric inhibin A
and B in spontaneous menstrual cycles. Journal of Clinical Endocrinology and
Metabolism 81, 2742-2745.
Krolner B, Pors Nielsen S (1982) Bone mineral content of the lumbar spine in
normal and osteoporotic women: cross-sectional and longitudinal studies. Clinical
Science 62, 329-336.
Larsen E C, Loft A, Holm K, Muller J, Brocks V, Nyboe Andersen A (2000) Oocyte
donation in women cured of cancer with bone marrow transplantation including total
body irradiation in adolescence. Human Reproduction 15, 1505-1508.
Larsen E C, Muller J, Rechnitzer C, Schmieglow K, Andersen A N (2003)
Diminished ovarian reserve in female childhood cancer survivors with regular
menstrual cycles and basal FSH <10IU/1. Human Reproduction 18, 417-422.
190
Laursen E M, Holm K, Brocks V et al (1996) Doppler assessment of flow velocity in
the uterine artery during pubertal maturation. Ultrasound Obstet Gynaecol 8, 341-
345.
Leiper A D, Stanhope R, Lau T, Grant D B, Blacklock H, Chessels J, Plowman P
(1987) The effect of total body irradiation and bone marrow transplantation during
childhood and adolescence on growth and endocrine function. British Journal of
Haematology 67, 419-426.
Leporrier M, von Theobald P, Roffe J L, Muller G. (1987) A new technique to
protect ovarian function before pelvic irradiation. Heterotopic ovarian
autotransplantation. Cancer 60, 2201-2204
Li T C, Dockery P, Ramsewak S S, Klentzeris L, Lenton E A, Cooke I D (1991) The
variation of endometrial response to a standard hormone replacement therapy in
women with premature ovarian failure. An ultrasonographic study. British Journal of
Obstetrics and Gynaecology 98, 656-661.
Littley M D, Shalet S M, Beardwell C G et al (1989) Hypopituitarism Following
External Radiotherapy for Pituitary tumours in adults. Quart J Med New Series 70,
145-160.
Lushbaugh C G, Casarett G W (1976) The effects of gonadal irradiation in clinical
radiation therapy: a review. Cancer 37, 1111-1120.
191
Mackie E J, Radford M, Shalet S M (1996) Gonadal function following
chemotherapy for childhood Hodgkin's disease. Medical and Paediatric Oncology
27, 74-78.
Manson JE, Hsia J, Johnson KC, Rossouw JE, Assaf AR, Lasser NL, Trevisan M,
Black HR, Heckbert SR, Detrano R, Strickland OL, Wong ND, Crouse JR, Stein E,
Cushman M; Women's Health Initiative Investigators. (2003) Estrogen plus
progestin and the risk of coronary heart disease. NEngl JMed 349, 523-534
Marshall W A, Tanner J M (1976) Variations in pattern of pubertal changes in girls.
Arch Dis Childhood 44, 291-303.
Mendlesohn M E, Karas R H (1999) The protective effects of oestrogen on the
cardiovascular system. The New EnglandJournal ofMedicine 340, 1801-1811.
Multidisciplinary Working Group convened by the British Fertility Society (2003) A
strategy for fertility services for survivors of childhood cancer. Human Fertility 6,
A1-A40.
Nasir J, Walton C, Lindow S W, Masson E A (1997) Spontaneous recovery of
chemotherapy induced primary ovarian failure: implications for management.
Clinical Endocrinology 46, 217-219.
192
Ng E H Y, Yeung W S B, Fong D Y T, Ho P C (2003) Effects of age on hormonal
and ultrasound markers of ovarian reserve in Chinese women with proven fertility.
Human Reproduction 18, 2169-2174.
Nicholson H S, Byrne J (1993) Fertility and pregnancy after treatment for cancer
during childhood or adolescence. Cancer 71, 3392-3399.
Noyes R W, Hertig A T, Rock J (1950) Dating the endometrial biopsy. Fertility and
Sterility 1, 3-25.
Nygaard R, Clausen N, Siimes M A et al (1991) Reproduction following treatment
for childhood leukaemia: a population based prospective cohort study of fertility and
offspring. Medical and Pediatric Oncol 19, 459-466.
Ogilvy-Stuart A L, Clark D J, Wallace W H B et al (1992) Endocrine deficit after
fractionated total body irradiation. Archives ofDisease in Childhood 67, 1107-1110.
Ogilvy-Stuart A L, Shalet S M (1993) Effect of Radiation on the Human
Reproductive System. Environ Health Perspec 101, 109-116.
Oktay K, Newton H, Gosden R G (2000) Transplantation of cryopreserved human
ovarian tissue results in follicle growth initiation in SCID mice. Fertility and Sterility
73, 599-603.
193
Oktay K, Nugent, Newton H (1997) Isolation and characterisation of primordial
follicles from fresh and cryopreserved human ovarian tissue. Fertility Sterility 67,
481-486.
Parkes A S (1957) Viability of ovarian tissue after freezing. Proceedings ofthe Royal
Society 147, 520.
Parrot D M V (1960) The fertility of mice with orthotopic ovarian grafts derived
from frozen tissue. Journal ofReproduction and Fertility 1, 230-241.
Pasqualini T, Escobar M E, Domene H et al (1987) Evaluation of gonadal function
following long-term treatment for acute lymphoblastic leukaemia in girls. American
Journal ofPediatric Haematology and Oncology 9, 15-22.
Paterson W F, Hollman A S, Donaldson M D (2002) Poor uterine development in
Turner syndrome with oral oestrogen therapy. Clinical Endocrinology 56, 359-365.
Pellicer A, Ballester M J, Serrano M D et al (1994) Aetiological factors involved in
the low response to gonadotrophins in infertile women with normal basal serum
follicle stimulating hormone levels. Human Reproduction 9, 806-811.
Piippo S, Lenko H, Kainulainen P, Sipila I (2004) Use of percutaneous estrogen gel
for induction of puberty in girls with Turner syndrome. Journal of Clinical
Endocrinology andMetabolism 89, 3241-3247.
194
Poirot C, Vacher-Lavenue M-C, Helardot P, Guilbert J, Brugieres L, Jouannet P
(2002) Human ovarian tissue cryopreservation: indications and feasibility. Hum
Reprod 17, 1447-1452.
Potashnik G, Lunefield E, Shwartz I et al (1995) Endogenous plasma growth
hormone and the occurrence of pregnancies in patients undergoing in-vitro
fertilization and embryo transfer with ovarian stimulation. Human Reproduction 10,
1065-1069.
Quigley C, Cowell C, Jimenez M et al (1989) Normal or early development of
puberty despite gonadal damage in children treated for acute lymphoblastic
leukaemia. The New England Journal ofMedicine 321, 143-151.
Radford J A, Leibermann B A, Brison D R et al (2001) Orthotopic reimplantation of
cryopreserved ovarian cortical strips after high-dose chemotherapy for Hodgkin's
lymphoma. Lancet 357, 1172-1175.
Register T C, Jayo M J, Jerome C P (1997) Oral contraceptive treatment inhibits the
normal acquisition of bone mineral in skeletally immature young adult female
monkeys. European Journal for Osteoporosis and the National Osteoporosis
Foundation 7, 348-353.
195
Reyes F I, Winter J S D, Faiman C (1997) Pituitary-ovarian relationships preceding
the menopause. American Journal ofObstetrics and Gynaecology 129, 557-564.
Royal College of Obstetricians and Gynaecologists (2000) Storage of Ovarian and
prepubertal Testicular tissue: report of a working party. London: Royal College of
Obstetricians and Gynaecologists.
Sanders J E, Hawley J, Levy W et al (1991) The impact of marrow transplant
preparation regimens on subsequent growth and development. Seminars in
Hematology 28, 244-249.
Sanders J E, Hawley J, Levy W, Gooley T, Buckner C D, Deeg H J, Doney K, Storb
R, Sullivan K, Witherspoon R, Appelbaum F R (1996) Pregnancies following high
dose cyclophosphamide with or without high dose busulphan or total body
irradiation and bone marrow transplantation. Blood 87, 3045-3052.
Sanders J E, Pritchard S, Mahoney P et al (1986) Growth and development following
marrow transplantation for leukaemia. Blood 68, 1129-1135.
Sarafogolou K, Boulad F, Gillio A, Sklar C (1997) Gonadal function after bone
marrow transplantation for acute leukaemia during childhood. Journal ofPediatrics
130,210-216.
196
Sauer M V, Paulson R J, Moyer D L (1997) Assessing the importance of endometrial
biopsy prior to oocyte donation. Journal ofAssisted Reproduction and Genetics 14,
125-127.
Scheffer G J, Broekmans F J, Dorland M, Habbema J D, Looman C W, te Velde E R
(1999) Antral follicle counts by transvaginal ultrasonography are related to age in
women with proven natural fertility. Fertility and Sterility 72, 845-851.
Scheffer G J, Broekmans F J, Looman C W, Blankenstein M, Fauser B C, te Jong F
H, te Velde E R (2003) The number of antral follicles in normal women with proven
fertility is the best reflection of reproductive age. Human Reproduction 18, 700-706.
Seifer D B, Gardiner A C, Lambert-Messerlian G, Blazer A S, Hogan J W, Berk C A
(1997) Day 3 serum inhibin-B is predictive of assisted reproductive technologies
outcome. Fertility and Sterility 67, 110-114.
Seifer D B, MacLaughlin D T, Christian B P, Feng B, Shelden R M (2002) Early
follicular serum mullerian-inhibiting substance levels are associated with ovarian
response during assisted reproductive technology cycles. Fertility and Sterility 77,
468-471.
Shaw J M, Bowles J, Koopman P et al (1996) Fresh and cryopreserved ovarian tissue
from donors with lymphoma transmit the cancer to the graft recipients. Human
Reproduction 11, 1668-1673.
197
Sherman B M, West J H, Korenman S G (1976) The menopausal transition: analysis
of LH, FSH, estradiol, and progesterone concentrations during menstrual cycles of
older women. Journal ofClinical Endocrinology andMetabolism 42, 629-636.
Shore R M, Chesney R W, Mazess R P, Rose P G, Bargman G J (1982) Skeletal
demineralisation in Turner syndrome. JMed Gen 19, 100-103.
Siris E S, Leventhal B G, Vaitukaitis J L (1976) Effects of childhood leukaemia and
chemotherapy on puberty and reproductive function in girls. The New England
Journal ofMedicine 294, 1143-1146.
Slemenda C W, Reister T K, Hui S L, Miller J Z, Christian J C, Johnston C C (1994)
Influences on skeletal maturation in children and adolescents: evidence for varying
effects of sexual maturation and physical activity. Journal ofPediatrics 125, 201-
207.
Snijders M P M L, de Goeij A F P M, Debets-Te Baerts M J C, Rousch M J M,
Koudstaal J, Bosman F T (1992) Immunocytochemical analysis of oestrogen
receptors and progesterone receptors in the human uterus throughout the menstrual
cycle and after the menopause. Journal ofReproduction and Fertility 94, 363-371.
198
Soules M R, McLachlan R I, Ek M, et al (1989) Luteal phase deficiency:
characterization of reproductive hormones over the menstrual cycle. Journal of
Clinical Endocrinology andMetabolism 69, 804-812.
Steer C V, Campbell S, Pampiglione J S, Kingsland R, Mason B A, Collins W P
(1990) Transvaginal clour flow imaging of the uterine arteries during the ovarian and
menstrual cycles. Human Reproduction 5, 391-395.
Stewart J R, Fajardo L F, Gillette S M et al (1995) Radiation Injury to the heart.
International Journal ofRadiation Oncology. Biology andPhysics 31, 1205-1211.
Syrop C H, Dawson J D, Husman K J, Sparks A E, Van Voorhis B J (1999) Ovarian
volume may predict assisted reproductive outcomes better than follicle stimulating
hormone concentration on day 3. Human Reprodroduction 14, 1752-1756.
Tavanioutou A, Smitz J, Bourgain C, Devroey P (2001) Ovulation induction disrupts
luteal phase function. Ann N YAcad Sci 943, 55-63
Taylor K J W, Burns P N, Wells P N T, Conway D I, Hull M G R (1985) Ultrasound
Doppler flow studies of the ovarian and uterine arteries. British Journal ofObstetrics
and Gynaecology 92, 240-246.
The European recombinant LH study group (1998) Recombinant human luteinizing
hormone (LH) to support recombinant human follicle-stimulating hormone (FSH)-
199
induced follicular development in LH- and FSH-deficient anovulatory women: a
dose-finding study. Journal of Clinical Endocrinology and Metabolism 83, 1507-
1514.
Tilly J L, Kolesnick R N (2002) Sphingolipids, apoptosis, cancer treatments and the
ovary: investigating a crime against female fertility. Biochem. Biophys. Acta, 1585,
135-138.
Tinkanen H, Blauer M, Laippala P, Tuohimaa P, Kujansuu E (1999) Prognostic
factors in controlled ovarian hyperstimulation. Fertility and Sterility 72, 932-936.
Tomas C, Nuojua-Huttunen S, Martikainen H (1997) Pretreatment transvaginal
ultrasound examination predicts ovarian responsiveness to gonadotrophins in in-vitro
fertilization. Human Reprodroduction 12,, 220-223.
Van Rooij I A, Broekmans F J, Te Velde E R, Fauser B C, Bancsi L F, Jong F H,
Themmen A P (2002) Serum anti-Mullerian hormone levels: a novel measure of
ovarian reserve. Human Reproduction 17, 3065-3071.
Wallace W H B, Kelsey T W (2004) Ovarian reserve and reproductive age may be
determined from measurement of ovarian volume by transvaginal sonography.
Human Reproduction 19, 1613 - 1618.
200
Wallace W H B, Shalet S M, Crowne E C et al (1989) Ovarian failure following
abdominal irradiation in childhood: natural history and prognosis. Clinical Oncology
1, 75-79.
Wallace W H B, Shalet S M, Lendon M, Morris-Jones P H (1991) Male fertility in
long term survivors of acute lymphoblastic leukaemia in childhood. International
Journal ofAndrology 14, 312-319.
Wallace W H B, Shalet S M, Tetlow L J, Morris-Jones P H (1993) Ovarian function
following the treatment of childhood acute lymphoblastic leukaemia. Medical and
Paediatric Oncology 21, 333-339.
Wallace W H B, Thomson A B, Kelsey T W (2003) The radiosensitivity of the
human oocyte. Human Reproduction 18, 1-5.
Wallace W H B, Walker D A (2001) Conference Consensus Statement: Ethical and
Research Dilemmas for fertility preservation for Children treated for cancer. Human
Fertility 4, 69-76.
Wallach E E (1995) Pitfalls in evaluating the ovarian reserve. Fertility and Sterility
63, 12-14.
Welt C K, Martin K A, Taylor A E et al (1997) Frequency modulation of follicle-
stimulating hormone (FSH) during the follicular-luteal transition: evidence for FSH
201
control of inhibin B in normal women. Journal of Clinical Endocrinology and
Metabolism 82, 2645-2652.
Welt C K, McNicholl D J, Taylor A E et al (1999) Female reproductive aging is
marked by decreased secretion of dimeric inhibin. Journal ofClinical Endocrinology
andMetabolism 84, 105-112.
Whitehead E, Shalet S M, Blackledge G, Todd I, Crowther D, Beardwell C G (1983)
The effect of combination chemotherapy on ovarian function in women treated for
Hodgkin's disease. Cancer 52, 988-993.
Yaron Y, Ochshorn Y, Amit A, Yovel I, Kogosowski A, Lessing J B (1996) Patients
with Turner syndrome may have an inherent endometrial abnormality affecting
receptivity in oocytes donation. Fertility and Sterility 65, 1249 - 1252.
Yong P Y K, Baird D T, Thong K J, McNeilly A S, Anderson R A (2003)
Prospective analysis of the relationships between the ovarian follicle cohort and
basal FSH concentration, the inhibin response to exogenous FSH and ovarian follicle
number at different stages of the normal menstrual cycle and after pituitary down-
regulation. Human Reproduction 18, 35-44.
Zelinski-Wooten M B, Lanzendorf S E, Wolf DP et al (1991) Titrating luteinizing
hormone surge requirements for ovulatory changes in primate follicles. I. Oocyte
202
maturation and corpus luteum function. Journal of Clinical Endocrinology and
Metabolism 73, 577-583.
Zevenhuijzen H, Kelnar C J H, Crofiton P M (2004) Diagnostic utility of a low-dose
gonadotropin-releasing hormone test in the context of puberty disorders. Hormone
Research 62,168-176.
203
